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ABSTRACT 
The need for improved adjuvants has continued in spite of new vaccination strategies using 
recombinant proteins and genetic (DNA vectored) vaccines. The Mycobacterium tuberculosis 
protein ESAT-6 has been shown in mice to be involved in the recall of long-lived immunity and 
protection in mice against tuberculosis. Thus, this protein could potentially act as a molecular 
adjuvant enhancing antigen-specific Type I immune responses. This study examined the 
hypothesis that Es could enhance Type I responses against a second antigen in mice when 
presented as a fusion with that antigen. This was tested using ESAT-6 fusions with two 
Mycoplasma hyopneumoniae surface antigens, P97 and P71, in mice either as recombinant 
proteins or as genetic vaccines. Control groups received no ESAT-6 sequences or no antigen or 
DNA. To accomplish this, gene sequences for the two proteins were identified and cloned with 
or without ESAT-6 sequences into expression or DNA vaccine vectors. This required 
modification of three TGA triplets in the P71 gene sequence. Following immunization, serum 
IgGl and IgG2a antibody levels and splenic lymphocyte antigen-speciHc blastogenic responses, 
and levels of IFN-y and IL-10 released were measured. 
The protein vaccination experiments revealed an elevated Thl response with the ESAT-6 
fusion vaccinates that was characterized by higher levels of IFN-y and suppression of IL-10 
secretion from the sensitized, antigen-stimulated splenocytes. The P71 protein vaccinates with 
ESAT-6 sequences had significantly higher levels of IgG2a compared to non-ESAT-6 P71 
vaccinates. The DNA vectored vaccination experiments gave similar results. Splenic 
lymphocytes from P71 vaccinates with ESAT-6 sequences secreted higher levels of IFN-y and 
lower levels of IL-10 when stimulated with P71 antigen compared to the non-ESAT-6 P71 
vaccinates. In addition, the experiments with genetic constructs for P71 revealed that the IgG2a 
antibody levels were significantly higher with the P71 vaccinates receiving ESAT-6 sequences 
compared to the non-ESAT-6 P71 vaccinates. In conclusion, ESAT-6 can act as a molecular 
adjuvant in mice to enhance antigen-specific Type I immune responses to both recombinant 
protein vaccines as well as genetic vaccines. 
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CHAPTER 1. INTRODUCTION 
Rationale and Hypothesis 
The primary goal of vaccination is to generate immunity in the host against invading 
pathogens or other pathological processes. Presentation of antigens to the host's inmiune 
system induces both humoral and cellular responses that involve critical memory control cells. 
The type of response is often modified by including adjuvants in the immunization protocol. 
Adjuvants play important roles in not only augmenting the immune response, but also in 
directing it toward a particular type of response (Type I or Type II). Common adjuvants include 
mineral oil, aluminum hydroxide, complete or incomplete Freund's adjuvants, or components of 
the mycobacterial cell wall. Our inability to control many infectious diseases, the rising 
incidence of antibiotic resistance, and the emergence of new pathogens or the re-emergence of 
existing pathogens has necessitated the exploration of more refined and effective adjuvants. 
Recently, there has been a development of new vaccination approaches, e.g., synthetic peptide or 
genetic vaccines, that can exploit the immune responses in novel ways to more effectively 
combat infectious diseases. The work presented in this dissertation represents a novel approach 
to enhancing antigen-specific Type 1 immune responses. A small protein from Mycobacterium 
tuberculosis, EAST-6 (Es), was shown previously to enhance the recall of long lived immunity 
by the generation of memory Thl cells that release increased levels of IFN-y. This effect was 
observed against Es when the protein was used to stimulate primed animals. 
The effect that Es might have on other antigen-specific immune responses is not known. 
The hypothesis for this smdy is that Es can enhance Type I responses against a second antigen 
in mice when presented as a fusion with that antigen. To test this hypothesis, a single specific 
aim was examined: can mice immunized with a fusion of Es and a second antigen generate an 
enhanced Type I response against the second antigen when compared to immunization with the 
second antigen alone? This specific aim was examined in both purified protein-immunized and 
genetic- (DNA vectored) immunized animals. If the hypothesis is true, Es could be considered 
as a molecular adjuvant that is useful in a wide variety of immunological applications. Two 
immunogenic surface proteins of Mycoplasma hyopneumoniae, P97 and F71, were chosen as 
the second protein antigens because of their potential as inmiunogens in vaccines against swine 
mycoplasma pneumonia. 
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Dissertation Organization 
This dissertation is organized in a standard format consisting of six sections, an 
Introduction, Literature Review, Materials and Methods, Results, Discussion and Conclusions. 
The Literature Review focuses on the significance of vaccination and on the types of adjuvants 
used to bring about immunomodulation, how the immune system responds to antigenic 
stimulation by regulating the type of response generated, and a history of the literature available 
on the Mycobacterium tuberculosis protein Es. Following the Conclusions is the Bibliography 
which follows the convention of the American Society for Microbiology. 
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CHAPTER 2. LITERATURE REVIEW 
Importance of Vaccination 
Infectious diseases continue to plague both human and animal populations in spite of 
increased availability of antibiotics and improved medical treatment worldwide. One of the most 
effective prophylactic measures to combat infectious diseases has been the use of vaccines, 
which enable the normal host to effectively fight invading pathogens. Unfortunately, effective 
vaccines are available for only a few pathogens. The dream of eradicating small pox in humans 
has been achieved by a global vaccination approach. In the case of animal diseases, attempts are 
being made to eradicate several diseases. Rabies has been eradicated from United Kingdom. 
Efforts are presently underway to control and eradicate several other infectious diseases 
afflicting both humans and animals, or zoonotic pathogens. There is also a class of pathogens 
referred to as emerging pathogens. These are pathogens that either emerged very recently in the 
world or are re-emerging after a period of dormancy. In this group are the HIV, Ebola, and 
Hanta viruses and Mycobacterium tuberculosis. Vaccination to prevent disease has evolved 
significandy since the early days of Edward Jenner's cow pox vaccination against small pox. 
Vaccines can come in several forms like live attenuated strains, killed whole cell preparations, 
purified components (i.e., membrane preparations) subunit vaccines, and genetically engineered 
components such as recombinant proteins, synthetic peptides or nucleic acids (DNA vaccines). 
There are constant efforts to continue improving vaccines to make them safer, more stable and 
more reliable. 
Immune Regulation 
The host immune response is carefully controlled by a complex network of immune effector 
cells, secreted proteins and cell-cell interactions. Specific immune responses can be broadly 
divided into two distinct compartments, humoral and cellular, that are interconnected. Each 
response can be fiirther subdivided by describing the cell types involved. T helper (Th) cells are 
CD4+, and are involved in regulation of both humoral and cellular responses. Two types of Th 
cells, Thl and Th2, fimction in concert to achieve regulation. The Thl/rh2 paradigm was first 
described following the discovery of distinct subsets of CD4-f T cell clones having discrete 
functional abilities in 1985 (S3). These cells had the capability to release unique profiles of 
cytokines that are associated either with inflammatory responses (Thl) or with B cell help 
(Th2)(67,93). Efforts to differentiate the two subsets by identifying specific surface antigens 
have not been successful. The Thl and Th2 subsets are most reliably distinguished by their 
pattem of cytokine production and functional responses. The Thl cells were shown to produce 
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IL-2, rFN-yand TNF-a and to mediate delayed type hypersensitivity (DTH) responses (19) 
whereas the Th2 cells produced IL-4 and IL-5 and induced isotype and class switching in B 
cells generating IgGl and IgE responses (22,52). A third subset of CD4+ T cells has been 
identified, called ThO cells, that produces a mixture of Thl and Th2 cytokine patterns (36). The 
Thl and Th2 effector cells seem to arise from a single precursor population of T cells with their 
functional phenotype committed within 48 hrs of antigenic priming (70). 
IFN-yand IL-I2 are considered the major cytokines promoting Thl differentiation from 
naive T cells (23). IL-I2 plays a pro-active role since its presence during priming directly 
augments Thl differentiation by preventing expression of IL-4 (70). The cytokines IL-4 and 
IL-IO are reported to promote Th2 differentiation (23), and IL-4 was shown to exert the most 
influence in controlling Th2 differentiation (95). 
Adjuvants 
Adjuvants are used in vaccine preparations to modulate the host's inunune response. There 
are several adjuvants available that are used for specific purposes based on the type of vaccine 
preparation, the species involved and the type of immunity involved. Different adjuvants 
produce variable immune responses under identical conditions and hence discretion has to be 
used in their choice. Similarly, recent advances in vaccinology, Uke DNA vaccines, have 
necessitated the development of newer types of adjuvants. 
Aluminum hydroxide is the most common adjuvant used in humans along with aluminum 
phosphate and calcium phosphate. Aluminum hydroxide and calcium phosphate have been used 
as adjuvants in both tetanus and diphtheria vaccines. Studies conducted in humans based on the 
levels of antibodies produced have revealed that calcium phosphate is more effective but is not a 
safer alternative to aluminum hydroxide when compared in vaccines containing 1.0 mg per ml 
of calcium or aluminum (2). Other studies conducted in mice and guinea pigs to check the 
potency of two diphtheria-tetanus vaccines adsorbed to either aluminum hydroxide or calcium 
phosphate showed that the adjuvanicity of calcium phosphate was lower than or equal to 
aluminum hydroxide (3). Aluminum hydroxide has been shown to have mucosal adjuvant 
activity in a tetanus toxoid vaccine. Administration of the vaccine intra-nasally produced high 
levels of tetanus toxoid (TT)-specific serum IgG antibody responses and moderate levels of TT-
specific IgA antibody responses in the nasal, pulmonary and small and large intestinal lavages 
(49). 
Aluminum hydroxide has also been used extensively, particularly in animal vaccines. For 
instance, aluminum hydroxide has been used in Mycoplasma hyopneumoniae vaccines using 
membrane preparations (57). Aluminum hydroxide has also been shown to be an effective 
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adjuvant for use in turkey E. coli vaccination without any adverse effect on body weight gain 
(99). In cattle and buffalo, an aluminum hydroxide gel vaccine against hemorrhagic septicemia 
caused by Pasteurella multocida has been found to be very effective (105). Mineral oil 
compared to aluminum hydroxide, however, led to better antibody production when tested as an 
adjuvant for an inactivated Mycoplasma agalactiae vaccine in sheep (17). 
Several other adjuvants are being tested like oil emulsions (68), muramyl dipeptide 
derivatives (31), the saponin Quil A (derived from the bark of Quillaja saponaria) (110), 
liposome encapsulation, and other synthetic compounds (42). Freund's complete or incomplete 
adjuvant (IFA) is used in lab animals (72, 84) along with several commercial preparations for 
use in farm and pet animals. 
Quil A has been shown to be an effective adjuvant for T independent antigens. It has been 
used as an adjuvant for polysaccharide based antigens from Escherichia co/i (110), 
Streptococcus pneumoniae (4,28), Borrelia burgdofferi{l8), meningiococcal organisms (104) 
as well as Actinobacillus pleuropneumoniae{J%) with very good results. Experiments with 
protein based antigens like Neisseria meningitidis ferric binding protein (fbpA) and P64k 
protein showed that Qui! A gave very good antibody responses (40,41). 
Several mycobacterial cell wall components have been shown to be very good adjuvants. 
The lipophilic derivative of muramyl dipeptide, Bacillus Calmette-Guerin cell wall skeleton as 
well as trehalose-6,6'- dimycolate has been shown to enhance the immunogenicity of 
recombinant human Hepatitis B surface antigen to induce humoral and cellular responses (58). 
Several cytokines are being tested as immunological adjuvants. Recombinant ovine IL-1 
alpha and beta have been shown to enhance the humoral immune response in an avidin test 
system (6). It has been shown that mtranasal immunization with liposomes containing 
Pseudomonas aeruginosa bacterial polysaccharide and cytokine IL-2 can lead to higher titers 
of IgA antibodies specific to the bacterial polysaccharide compared to immunization with 
liposomes containing the bacterial polysaccharide alone (1). Not all tests have been successful, 
however. Bovine recombinant IL-2 has been examined in a Staphylococcus aureus vaccine in 
cattle with little efficacy (27). 
The choice of adjuvant can alter the type of immune response induced in the host For 
instance, aluminum hydroxide was found to induce a Th2 humoral response (mostly IgGl) in a 
mouse Hepatitis B surface antigen immunization model while CpG oligodeoxynucleotides 
when used as an adjuvant favored a strong Thl type response with predominantly IgG2a 
antibodies and cytotoxic lymphocytes. The combination of aluminum hydroxide plus CpG 
ODN led to a strong synergistic interaction with higher antibody titers than when aluminum 
hydroxide was used as the adjuvant alone (25). A greater Thl type of response in BALB/c 
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week-old mice was demonstrated using block copolymers in a water-in-oil emulsion adjuvanted 
vaccine. However, this Thl response enhancing adjuvant had to be used at the time of primary 
vaccination in order to fiilly circumvent the persisting influence of Th2- biased neonatal 
responses (7). 
Under normal conditions, exogenous proteins are presented in association with major 
histocompatibility complex (MHC) class II molecules while an endogenously produced protein 
will be presented with the MHC class I molecule. Activation of CDS cells leading to a cytolytic 
response normally can only be elicited with endogenously produced proteins, since it requires 
MHC class I presentation. This process can be circumvented, however, using novel approach to 
present an exogenous protein in association with MHC class I molecules. Fusion of that protein 
to the binding and translocating domains of Pseudomonas exotoxin A that can lead to its MHC 
class I presentation (29), thereby enhancing Thl responses. 
Cytokines have been shown to be effective modulators of immune responses across species. 
Vaccinating pigs with a Streptococcus suis vaccine in combination with recombinant bovine IL-
l beta or IL-2 has been shown to be more effective than the vaccine alone (12). Cytokines such 
as IL-1, IL-2, IL-3, IL-6, IL-12, IFN-y, tumor necrosis factor (TNF), and granulocyte monocyte 
colony stimulating factor (GM-CSF) have been shown to have vaccine adjuvant activity as well 
(71). 
The presence of bacterial DNA sequences in DNA vaccines was found to have potent 
stimulatory effects on the vertebrate immime responses. This was attributed to the presence of 
CpG motifs present in bacterial DNA sequences. The CpG motif that can lead to optimal B-cell 
activation requires an unmethylated CpG dinucleotide flanked by two 5' purines and two 3' 
pyrimidines (59). Synthetic oligodeoxynucleotides (ODN) can be made nuclease resistant and 
may substitute for bacterial DNA in DNA vaccines. These ODNs contain unmethylated CpG 
dinucleotides within the context of certain flanking bases (the CpG motif) that are similar to the 
ones found in bacterial DNA. It appears necessary to clone CpG motifs into DNA vaccine 
vectors to take advantage of their adjuvant effect, however. Experiments conducted by Weeratna 
et. al. (109) have shown that it is not possible to mix ODNs with plasmid DNA, because it will 
result in an ODN dose-dependent reduction in gene expression from the plasmid. This may be 
explained by competitive interference at binding sites on the surface of target cells. Studies have 
shown that CpG ODNs act as promising new immune enhancers for vaccine applications by 
inducing expression of co-stimulatory molecules on antigen-presenting cells and by enhancing 
B cell isoQrpe switching in the appropriate cytokine milieu (25). 
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ESAT.6 
The central hypothesis of this study focuses on the unique immunological qualities of the 
mycobacterial protein Es. This protein has been shown to stimulate long-lived cellular immunity 
to M. tuberculosis in human patients. Previous studies have focused on Es-specific responses, 
and no studies have been performed on Es-enhanced immune responses in relation to other 
non-mycobacterial proteins. 
Immunology 
The inmiunologic properties of Es have been studied in both animals and humans. This 
antigen is a prominent target recognized early during disease in mice (5), cattle (76) and humans 
(77). Es was originally identified as a potent inducer of IFN-yfrom mouse memory Thl type 
lymphocytes. Recent studies have shown that in human tuberculosis patients, it acts as the most 
potent inducer of IFN-y from among a large panel of purified mycobacterial antigens tested (69, 
77). 
In the mouse model of memory immunity to tuberculosis infection, the recall of long-lived 
immunity has been attributed to proteins Ag85B and Es. The recall of immunity is expressed as 
an accelerated accumulation of potent effector cells in the infected target organs when the host 
sees the pathogen for a second time. This recall of immunity was found to be very efficient and 
could control infectious challenge within the first week. The memory effector cells of the CD4 
class were found to reside predominantly in the dMSRB'"* CD44'"*'' LPA-l'"®'' L-selectin'"" 
pool of cells. These effector cells exerted their functions by massive release of Thl cytokine, 
IFN-y(5). 
It was shown in a study that the first significant T cell response in cattle that were 
experimentally infected with M. bovis occurs 3 weeks after the onset of infection. It was 
characterized by a pronounced IFN-y response from peripheral blood mononuclear cells 
directed to antigens in culture filtrate. The major T cell target responsible for this dominant 
IFN-y response during the early stage of infection was identified to be the secreted antigen Es 
(76). 
Epitope mapping 
The T cell epitope on the Es molecule was mapped using 20 amino acid synthetic peptides 
spanning the complete sequence of M. tuberculosis Es in different inbred strains of mice 
representing different haplotypes (IS). The epitope recognized in the context of H-2b and H-2d 
haplotypes (C57BL/6j and BALB/c mice respectively) was found to reside within the first 20 
amino acids at the N terminal end of Es. A second epitope was recognized in the context of H-
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2a (A/J mice) and H-2k (CBA/J and AKR/N mice) haplotype that covered amino acids from 51 
to 60. The amino acids representing the core epitope of the N-terminal end of Es recognized in 
the context of H-2b was further mapped precisely to amino acids from position 3 to 15 (15). 
Fine specificity of the T cell responses to Es mapped using synthetic 24 mer peptides with a 
14 amino acid overlap in human mberculosis padents indicated that this small molecule contains 
an unusually high number of T cell epitopes sparming the entire sequence of the antigen. It was 
observed that while all the peptides from Es were able to induce a T cell response in some 
persons, some of the peptides were able to induce even higher levels of IFN-y compared to that 
induced by the intact molecule. An HLA-DR7 and an HLA-DPB 1*0401 epitope has been 
predicted within the Es located in amino acids 42 to 52 and 73 to 81 respectively. The HLA-
DPB 1*0401 epitope has been shown to correspond to the C terminal amino acids 72 to 95 
region of Es (77). It has also been shown that the C terminal end of Es is recognized by IFN-y 
secreting human CDS T cells (61). 
Mapping of the T cell epitopes in Es responsible for enhanced release of IFN-y from 
stimulated T cells of tuberculosis patients focused on the N terminal portion of the protein. Two 
of the synthedc peptides consisting of amino acids 1 to 20 and 10 to 30 were recognized to be 
epitopes for HLA-DR haplotype based on their stimulating capacity to enhance IFN-y 
responses from activated sensitized T cells (103). Based on the above findings, Es epitopes can 
be considered to stimulate both CD4 and CDS T lymphocytic responses against M. 
tuberculosis infection in humans. 
Es has also been shown to elicit delayed type hypersensitivity (DTH) skin responses in 
outbred guinea pigs infected with Af. tuberculosis by the aerosol or intravenous route, but not 
with those sensitized with M. bovis BCG or M. avium. The DTH epitope was mapped to the C 
terminus of the Es protein comprising the amino acids 72 to 95 (32). In another experiment, it 
was recognized that the T cells recruited during delayed type hypersensitivity to purified protein 
derivative differed markedly from those recruited during challenge with M. tuberculosis in 
immunized mice. The T cells recruited during DTH to purified protein derivative (PPD) 
recognized the secreted mycobacterial protein Ag85B and the heat shock proteins, DnaK and 
GroEL while those involved with protection were characterized by the majority of T cells 
directed to the Es peptide consisting of amino acids 1 to 20. It was also shown that by adoptive 
transfer of the purified CD4+ memory effector cells from memory immune mice, both DTH to 
PPD as well as protection to nude mice can be effected (73). 
Experiments aimed at mapping the B cell epitope precisely mapped the epitope for the 
monoclonal antibody HYB76-S to the amino acid residues from 3 to 15 of Es. The 
hydrophilicity plot of Es reveals two more hydrophilic areas one from amino acid 30 to 38 and 
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another from amino acid 50 to 59 in addition to the N terminal one. In order to find out 
whether those hydrophilic areas contained surface exposed parts of the polypeptide chain with 
B cell epitopes, antibodies were raised against synthetic peptides corresponding to positions 30 
to 38 and 51 to 59. Those antibodies did not react with native Es m Western blotting or in 
capture ELISA with HYB76-8 monoclonal antibody. However, generating antibodies against a 
synthetic peptide containing residues 40 to 62 identified a second B cell epitope that could be 
used in a double antibody ELIS A for estimation of Es in Af. tuberculosis antigen preparations 
(44). 
Genetics 
Es is present in all pathogenic mycobacterium strains belonging to the M. tuberculosis 
complex (A/, tuberculosis, M. africanum, and M. bovis) and several others like M. kansasii, M. 
szulgai, and M. marinum (92), but has not been shown in any of the 8 substrains of M. bovis 
BCG strain, Af. avium, Af. leprae, M. scrofulaceum, M. intracellulare, M. fortuitum or Af. 
xenopi. Es gene was found at identical locations on the chromosome within species belonging 
to the M. tuberculosis complex by southem blot studies (45). The absence of Es on all BCG 
substrains was confirmed by subtractive genomic hybridization between virulent M. bovis and 
avirulent BCG. Three regions of difference designated RDl - RD3 were detected between the 
virulent M. bovis and the attenuated vaccine strain Af. bovis BCG. While RDl was detected in 
strains of Af. tuberculosis and M. bovis, it was absent in all BCG substrains. The gene encoding 
the early secreted antigenic target 6 kDa protein is found within the RDl region as an open 
reading frame having 285 nucleotides where it was provisionally referred to as orflC (64). The 
gene for Es is downstream of a novel gene designated Ihp that codes for another small protein 
of 10 kDa as part of an operon. A Rho-independent uranscription terminator is present 40 bp 
downstream from the esat-6 stop codon. Es and CFP-10 {Ihp gene product) are co-transcribed 
and share the same messenger RNA transcript, have similar molecular masses and are detected 
in the extracellular media during broth culture of M. tuberculosis. Both Ihp and esat-6 genes are 
deleted in A/, bovis BCG (9,10). 
Biochemistry 
The Es protein secreted by M. tuberculosis was initially purified from short-term culture 
filtrate by hydrophobic interaction chromatography followed by anion exchange 
chromatography. Es was shown to occur in two different pi forms. The two isoforms of the 
purified protein obtained either from short-term culture filtrate or of the purified recombinant 
protein followed by immunoblotting were shown to have pi within the range of 4 to 4.5 by two 
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dimensional electrophoresis. It was suggested that modification of the protein such as by 
deamidation of amide side chains or oxidation or phosphorylation could explain that 
observation. Es was found to have a molecular mass of 24 kDa under non-denaturing 
conditions during either size chromatography or PAGE, indicating that the native protein may 
exist as a polymer (92). The presence of a signal sequence has not been identified, and it is 
thought that Es is released from the mycobacterial cell by a signal peptide-independent process 
(45). 
Use as a diagnostic reagent 
The uniqueness of having Es present in only pathogenic mycobacteria, led to the suggestion 
that this antigen could form the basis of a specific diagnostic test or be a component of a 
vaccine (76). Large-scale diagnostic strategies for tuberculosis in both human and cattle depend 
on inU^dermal tuberculin test that measures delayed type hypersensitivity reactions to a poorly 
defined mycobacterial extract, such as purified protein derivative. The use of this poorly defined 
antigen leads to a lack of specificity. In order to increase the specificity of the tuberculin test, 
responses to PPD prepared fi-om mycobacteria belonging to the tuberculosis complex are 
compared with responses to PPD derived firom environmental mycobacteria. This comparative 
intradermal testing has been used for both humans (106) and cattle (66). An improved method 
over the intradermal skin test is a blood test based on in vitro detection of IFN-y released in 
response to PPD for detecting bovine tuberculosis (112). The feasibility of the use of Es as a 
purified antigen in the diagnosis of field cases of bovine tuberculosis was first demonstrated by 
Pollack and Andersen in 1997 (75). 
One of the major hurdles in the use of attenuated mycobacterial strains like BCG for 
vaccination of humans and cattle is its interference with the detection of tuberculosis by means 
of the tuberculin skin test. In an attempt to develop a test that would distinguish between an 
early infection with M. bovis and vaccination with BCG, four major secreted proteins of M 
bovis viz. MPB59, MPB64, MPB70 and Es were tested in a whole blood IFN-y assay. Es was 
found usefiil to differentiate between Mycobacterium bovis BCG-vaccinated and M. bovis 
infected cattle in the assay along with bovine purified protein derivative. Cattle from both the 
BCG vaccinated as well as the non-vaccinated groups that were M. bovis culture positive 
following challenge produced strong IFN-y responses to bovine purified protein derivative and 
Es of all the proteins tested in a significant manner compared to those observed with the 
corresponding M. bovis culture negative animals. This finding indicated that Es could be used 
as a reagent to discriminate between an active disease from exposure to M bovis and BCG-
vaccinated, non-infected cattle (16). 
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In another effort to develop an accurate sero-diagnostic test for bovine tuberculosis, the 
circulating IgG antibody levels were measured in sequential serum samples collected from 
experimentally infected catde by ELISA using several purified recombinant proteins of M 
bovis. Kinetic analysis of the antibody production indicated that the humoral inunune response 
in experimental bovine tuberculosis involves multiple antigens that are differentially recognized 
in different animals and at different stages of the disease in the same host. Es and 14-kDa 
proteins are the only antigens that display potent sero-reactivity in both human and bovine 
tuberculosis. This suggests that no single antigen could be used as a sero-diagnostic reagent 
thereby requiring the development of a multi-antigen based sero-diagnostic approach (63). 
DNA Vaccines 
One of the more exciting developments in vaccinology over the past decade has been in the 
use of naked DNA for vaccination (referred to as DNA vaccines or genetic vaccines). The use 
of DNA in vaccinations was first conceptualized when Wolff and associates (111) showed that 
a protein can be expressed in vivo by merely injecting an expression plasmid containing the 
gene for that protein into muscle. They used the genes for chloramphenicol acetyltransferase, 
luciferase and P-galactosidase as reporter genes to monitor gene transfer and expression in a 
mouse model. Expression plasmids containing any one of the above mentioned genes when 
injected into mouse skeletal muscle in vivo, led to detectable protein expression as measured by 
their respective enzyme assays. In sim cytochemical staining also showed that the (3-
galactosidase activiQr was restricted to the muscle cells located at the site following injection of 
the p-galactosidase-producing DNA vector. Interestingly, this in vivo expression procedure did 
not require any special delivery system other than direct injection of the expression construct 
into the muscle (111). 
The central theory for DNA vaccination is that transfected cells will transcribe and translate 
cloned genes, and the resulting products are presented to immune effector cells producing both 
humoral and cellular immune responses (101, 102). The introduction of DNA into a cell is a 
transfection process, but its presentation to the cell can occur by several routes. These include 
injection of plasmid DNA in saline in muscle (35,38,111), the use of a gene gun that can fire 
DNA-coated microscopic gold beads into cells (35,38), and by use of an infectious agent that 
has been stripped of the genes necessary for virulence or replication (33,74,83,90). DNA 
vaccine technology has been found effective and its use may accelerate due to several 
advantages. 
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DNA vaccines use eukaryotic expression vectors to produce the immunizing proteins in the 
vaccinated host (81). This technique of introducing naked DNA into the body is fast evolving 
into an effective and powerfiil means to produce more effective vaccines (13,80,100,107,108). 
Advantages of DNA vaccines 
There are several advantages for DNA vaccines over conventional vaccines. DNA vaccine 
preparations are less expensive in most cases than more conventional vaccines. They are more 
stable and do not require refrigeration. They have longer shelf lives, and they are safer because 
the antigens produced have been well characterized. DNA vaccines are similar to live attenuated 
or live recombinant vectors in that they produce the immunogen within the host, but there is no 
risk of infection with DNA vaccines (79,81). They combine the safety of a subunit vaccine with 
the efficacy of a live virus vaccine (20). Whenever attenuated strains are used, reversion to 
wildtype is possible (24). 
When antibody responses against conformational epitopes are required for protection, the 
native form of the protein must be used in vaccines. Delivery of the immunogen as a DNA 
vaccine can ensure production of the protein in native form thereby effecting a more protective 
antibody response. This is especially important for viral proteins since they are expressed in 
their native confirmation during replication in the host cell. These types of epitopes can easily 
be disrupted during the in vitro recombinant protein production and purification processes (79). 
DNA vaccination can be a very powerful vaccination approach against intracellular 
pathogens that require a cytolytic response. It was once believed that live agents were required 
for cytolytic responses, but it is now known that DNA vaccination can produce cytotoxic 
lymphocytes. Vaccinating using DNA can lead to antigen processing and presentation by both 
Class I and Class Q MHC molecules (81). The transfected antigen-presenting cells can present 
the antigen by Class I MHC while the protein that has been taken up by phagocytosis by other 
cells can be presented in the context of Class II MHC. This can lead to both cytolytic and 
antibody production directed against the cloned immunogen whereas classical subunit vaccines 
are primarily limited to antibody production (79). DNA vaccination can lead to long lived 
immune responses unlike killed vaccines that require multiple vaccinations for long term 
protection. This can reduce the cost of vaccination (79). DNA vaccination may facilitate 
combination vaccines. The differences in the formulation of different conventional vaccines limit 
their use in combination. This can drastically cut the cost of vaccine production as well as health 
care expenses due to reduced administration costs (79). 
Unlike conventional vaccines that require proprietary discrete protocols, all DNA vaccines 
can be produced using similar fermentation, purification and validation techniques. This would 
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vastly simplify vaccine development and production (34). In conventional vaccine preparations, 
care has to be taken to prevent carry over of bacterial proteases from the cell cultures that can 
cause degradation of purified components. Similarly, specialized procedures like freeze-drying 
is required to achieve high stability of purified bacterial polysaccharides. Catalytic degradation 
may occur, however, if the stabilizers are of inadequate purity (24). When exposed to adverse 
conditions, live attenuated vaccines such as BCG and typhoid vaccines can lose potency through 
loss of viability (24). However, DNA vaccines do not require the cold chain that is necessary 
with conventional vaccines since DNA vaccines are stable over a wide temperature range (34, 
81). This would vastly reduce the cost of vaccination and will play an important role in 
eradicating diseases that are prevalent in third world countries. 
DNA vaccines can be developed from infected tissues when the pathogen is uncultivable or 
a slow grower. The cloning of relevant genes can be accomplished by PCR. This can speed up 
the process of vaccine development because it eliminates the several days or weeks needed to 
isolate and grow a pure culture of slowly growing pathogens. It is the only feasible altemative 
with uncultivable pathogens (81). The entire genome of a microbe can be tested for the 
appropriate vaccine sequences by expression library immunization (8). 
Immunomodulation 
The type of immune response elicited will depend on whether the antigen is presented by 
class I or class II MHC molecules. It is possible to construct DNA vaccines that would favor 
presentation of antigens by a particular class of MHC molecule. Fusing immunogen sequences 
with ubiquitination sequences (37,82, 113) or to endoplasmic reticulum retention sequences 
(21) can favor MHC class I presentation while fusion to secretory signals can favor MHC class 
n presentation (14). 
The use of "designer" genes for DNA immunization can help to alter the immune 
responses more towards a Thl or Th2 type response. Designer genes include gene sequences 
that represent the cytotoxic T lymphocyte (CTL), B and T helper cell epitopes and fusions of 
immunogens with leader, ubiquitination, lymphokine and tetanus toxin sequences. It has been 
shown that fusing proteins to leader sequences can result in secretion of the immunogen leading 
to a more favored Th2 type response. Mice when immunized with a DNA constmct that will 
cause secretion of ovalbumin showed high levels of IgGl while mice immunized with DNA 
construct that expressed the immunogen in the cytoplasm showed higher levels of IgG2a 
antibody (14). 
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The method of DNA inimunization can also affect the type of response generated. DNA 
saline injections that elicit primarily a Thl response can be shifted toward a Th2 response by 
immunizing muscle using a gene gun (35). 
Tmmiinnmodulation is also possible in DNA vaccines by combining cytokine and 
immunogen genes (43,96). Co-expressed modulators tested in DNA vaccines include the 
cytokines GM-CSF (89), IL-12 (54), IL-2, IL-4, IL-10, IL-15 and IL-18 (88) and other co-
stimulatory molecules like B7.1, B7.2 (50) and CD86 (55). It was suggested that B7.1 
promotes both Thl and Th2 responses, while B7.2 preferentially favored Th2 responses (26). 
Limitations of DNA vaccines 
DNA vaccines offer great potential in the area of vaccine development, but they also have 
some limitations. Since DNA vaccines can code only for protein antigens, it may not be 
possible to mount an inunune response against the capsular polysaccharide component or the 
lipid component of antigenic lipoproteins of pathogens. True mucosal delivery of DNA 
vaccines seems to be a distant goal at the moment, even though modified gene guns have been 
tested for vaccination in the throat mucosa. New DNA delivery techniques are required for 
effective mucosal immune responses. Successful mucosal immunization by intra nasal 
administration of DNA has been reported in mice (60), however. Conventional vaccines (e.g., 
oral polio vaccine) have an upper edge in developing immune responses at mucosal sites where 
the host will encounter the pathogen for the first time. 
The proteins synthesized by bacteria and other parasites can undergo distinctive patterns of 
protein modification that cannot be emulated by DNA vaccination. However, this has not 
hindered the use of DNA vaccination for parasitic and bacterial agents. DNA vaccines have 
been successfully used in animal models against bacterial pathogens. Studies that showed 
protection include Mycoplasma pulmonis (genomic expression library)(8), Leishmania major 
(114), M. tuberculosis (Ag85 and hsp65)(48,62,97), and the malarial parasite circumsporozoite 
protein (30,86). 
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MATERIALS AND METHODS 
Bacterial Strains and Plasmids 
Escherichia coli strains LE392 (F hsd514{rk', mk')lacY supE44 sup F5 galK2 galT22 
trpR55 metBl X,") and TOPIO (F mcrA ^ (mrr - hsdRMS - mcrBC) (|>801ac AA/i5 MacX74 
deoR recAl araD139 Miara - leu)7697 galU galK rspL endAl nupG) were obtained from lab 
stocks maintained at -70°C and were grown in Luria Bertani or super broth media (85). 
Plasmids used in this study are described in Table I. The pTrcHis plasmids were obtained from 
Invitrogen, Inc.(Carlsbad, Calif.). The mammalian expression plasmids pVR1012 and pVR1020 
were gifts from Vical, Inc. Plasmid pA containing the M. tuberculosis Es gene was a gift from 
Dr. Greg Mahairas at the University of Washington. The pMYC0161 plasmid that has the 
TGA-modified Mycoplasma hyopneumoniae P97 gene was a gift from Dr. Kendall King. 
Plasmids were stored at -20°C. 
Reagents and Buffers 
Molecular biology chemicals and reagents were purchased from Sigma Chemical Co. (St. 
Louis, Mo.), Restriction enzymes, 1 kb and 123 bp DNA ladders, Taq and Pfu DNA 
polymerases, T4 DNA ligase, calf intestinal alkaline phosphatase and DNase were purchased 
from Promega Corporation (Madison, Wis.), GIBCO BRL (Gaithersburg, Md.), Sigma, 
Qiagen, Inc. (Chatsworth, Calif.), Stratagene (La JoUa, Calif.) or New England Biolabs (Beverly, 
Maine). Agarose was purchased from Bio-Rad Laboratories (Hercules, Calif.), Synergel from 
Diversified Biotech (Boston, Mass.), isopropyl thio-P-D-galactoside (IPTG) from Gold 
Biotechnology, Inc. (St. Louis, Mo.), deoxynucleotides (dNTPs) from Amersham Pharmacia 
(Piscataway, N.J.), and methyl [H^] thymidine from Amersham Life Science (Arlington 
Heights, ni.). 
Genomic Library Screening and Plasmid Analysis 
A M. hyopneumoniae genomic library constructed in Lambda ZAP n (Stratagene, La Jolla, 
Calif.) was screened with convalescent, challenge-protected swine sera S195 (65). The cloned 
fragments were excised in vivo (87), and the resulting recombinant plasmids were subjected to 
restriction enzyme analysis and restriction site mapping. Five of the 12 immunopositive clones 
overlapped a single chromosomal region. One of the clones, pISM2151, was subjected to 
TnJOOO mutagenesis (94), and the transposon inserts were mapped by restriction digests. A 
series ofTnlOOO inserts spanning the cloned fragment were analyzed for loss of 
immunoreactivity using swine serum S195, and the region of the cloned fragment expressing 
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Table 1: Plasmids, 
Plasmid Genotype or phenotype Source 
pA Es ORF containing plasmid G. Mahairas 
pMYCO P97 gene containing plasmid K. King 
PISM2137 
pISM403 pTrcHis B:Es this study 
pISM404 pTrcHis B:Es (no stop codon with BamHl site)* this study 
pISM405 pTrcffis A:P97 this study 
pISM406 pISM404:P97 cloned into BamiQ. site this study 
pISM407 pTrcHis A:P71 this study 
pISM408 pTrcHis Arfragment ABC of P71 this study 
pISM409 pISM408 + fragment D of P71 this study 
pISM410 pISM404:P71 (modified ORF cloned into BamlU site) this study 
pISM411 pVR1012:Es this study 
pISM4I2 pVR1012:Es (no stop codon with BamHl site)* this study 
pISM413 pVR1012:P97 this study 
pISM414 pISM412:P97 (cloned into BamlU. site) this study 
pISM415 pVR1012:P71 (TGA modified ORF) this study 
pISM416 pISM412:Es:P71 (TGA modified ORF cloned into this study 
BamHl site) 
pISM417 pVR1020:Es this study 
pISM4I8 pVR1020:Es (no stop codon with BamHl site)* this study 
pISM419 pVR1020:P97 this study 
pISM420 pISM418:P97 (cloned into BamHl site) this study 
pISM421 pVR1020:P71 (TGA modified ORF) this study 
pISM422 pISM418:P71 (TGA modified P71 ORF cloned into this study 
BamHl site) 
* The Bam¥l site is used for making protein fusions. 
the antigenic epitope identified. To facilitate DNA sequencing a deletion was constructed in 
pISM2137 by removing a Hindm fragment from one end of the fragment. The resulting clone, 
pISM2137A, was subjected to DNA sequence analysis using TnlOOO inserts as primer sites as 
well as vector sequences (94). 
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Site-Directed Mutagenesis 
Site-directed mutagenesis was performed to convert TGA triplets to TGG triplets in the P71 
gene sequence. The method used was overlap extension PGR (39). The primers used in this 
smdy are described in Table 2. Complementary primers were designed with the TGA triplet 
substituted with TGG within the primer sequences and the optimum reaction parameters defmed 
using Oligo primer analysis software (National Biosciences, Inc., Plymouth, Minn.). The 
strategy involved the joining of the FCR-generated overlapping fragments having the required 
mutations by several rounds of overlap extension and polymerase chain reactions. The strategy 
is depicted in Figure 1. 
All PGR reactions were performed using Pfu DNA Polymerase following standard 
protocols. Hot start PGR was commonly used. Standard PGR conditions were as follows: 500 
ng of template DNA, primers (0.5 pM final concentration), dNTPs (200 ^M), 2 mM MgGlj in 
a total volume of 100 pi. Fragments A, B, G and D were generated using pISM407 as the 
template DNA. The cycUng conditions were: one cycle of denaturation at 94°C for 2 min; 30 
cycles of amplification (denaturation at 94°C for one min; anneaUng at 45°C for 45 sec, 
extension at 72°C for 2 min), and a fmal polishing step at 72°G for 10 min. 
Overlap extension mixtures contained equal molar amounts of the two fragments (500 -
10(X) ng per reaction) without primers. The reaction mixture also contained an additional 1 mM 
MgCIj (total of 3 mM). The cycling conditions for overlap extension were the same as for the 
generation of individual fragments except for the changes as follows. The annealing temperature 
was raised to 50°G after the first 5 cycles, and the total number of cycles in segment two was 
lowered to 20 for generating fused fragments AB and BG. For generating the ABG fragment, 
the annealing temperature was 50°G followed by 15 cycles at an annealing temperature of 57°G. 
PGR amplification of the fused fragments with their respective primers was performed with the 
following cycling condition changes: the annealing temperature was 45°G for 45 sec for the first 
10 cycles followed by 50°G for 45 sec for the rest 20 cycles. The reaction mixture contained an 
additional ImM of MgGlj. 
Fragment lengths were verified by running the PGR products in synergel: agarose 
(0.65%w/v: 0.7%w/v) gel using the 123 bp DNA ladder as a size standard. Standard TBE 
buffer (85) was used as the electrophoresis buffer. PGR products were purified using 1.5% 
agarose gels. The bands representing the specific fragments were cut out and spun through 
DNA extraction spin column (Supelco, Bellefonte, Penn.) in a refiigerated microfiige. The 
eluate containing the purified fragment was concentrated using QIAEXII gel extraction kit 
(Qiagen Inc., Ghatsworth, Galif.). 
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Table 2. Primers. 
Name Function Plasmids* Sequence (5 -3 ) 
P71.1 
P7I.2 
P71.4 
FP71.S1 
RP71.S1 
FP71.S2 
RP71.S2 
FM71.S3 
RM7I.S 
3 
FP71.S3 
Forward primer of 
P71 gene with 
BgHl site 
Reverse primer of 
P7l gene with 
BglO. site 
Forward primer of 
P71 gene with 
ATG start codon 
and BgHl site 
Forward primer for 
STM with the first 
TGA triplet ofP7l 
ORE mutated to 
TGG 
Reverse primer for 
STM with the first 
TGA triplet of P71 
ORE mutated to 
TGG 
Forward primer for 
STM with the 
second TGA triplet 
ofP7I ORF 
mutated to TGG 
Reverse primer for 
STM with the 
second TGA triplet 
ofP7I ORF 
mutated to TGG 
Forward primer 
with BamHl site 
for cloning 
fragment IV of P7I 
Reverse primer 
with BamHl site 
for generating 
fragment (1-2-3) of 
P71 for cloning 
Forward primer for 
STM with the third 
TGA triplet of P7l 
ORF mutated to 
TGG 
407, 408, 410, 
416. 421, 422 
407, 409, 410, 
415, 416, 421, 
422 
415 
NA 
NA 
NA 
NA 
409 
408 
NA 
GCrAGATCnTGCAAAAAAATTCTTTGCTTTC 
GCTAGATCTTTAGTTTGAnTAGGCTCGGTA 
C 
GCTAGATCTATGCAAAAAAATTCTTTGCTTT 
C 
GGGACAACAACAGAAAACTGGCTTTACC 
GGTAAAGCCAGTTTTCTGTTGTTGTCCC 
GAATTTAAAAAATGGGCAAGTATAATAAAA 
CC 
GGTTTTATTATACTTGCCCATTTTTTAAATT 
C 
TGAAAGGATCCTGATAAAAATITAATGGCG 
AA 
ATCAGGATCCTTCCAAATACmTATCATA 
GAC 
GATGTCTATGATAAAAGTATTTGGAATGATr 
CTG 
* Primers were used in the indicated pISM plasmid constructions 
Table 2, (continued). 
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RP71.S3 
FlEs 
RlEs 
R2Es 
F2Es 
FMhp3 
RMhp3 
FMhp4 
pTH-SP 
VR1020-
SP 
VR1012-
SP 
Reverse primer for NA 
STM with the third 
TGA triplet of P71 
ORF mutated to 
TOG 
Forward primer for 
Es ORF with /H 
site (reading frame 
n) 
Reverse primer for 
Es ORF with BgUl 
site 
Reverse primer for 
Es ORF with 
BamHl site and the 
stop codon 
removed 
Forward primer for 
Es ORF with BgHl 
site (reading frame 
D 
Forward primer for 
P97 ORF with 
Bc[l site (reading 
fnime 0 
Reverse primer for 
P97 ORF with 
BcH site 
Forward primer for 
P97 ORF with 
BcH site (reading 
fhime I) and ATG 
start codon 
Sequencing primer NA 
forpTrcHis 
plasmid derivatives 
Sequencing primer NA 
for pVR 1020 
plasmid derivatives 
Sequencing primer NA 
forpVR1012 
plasmid derivatives 
403, 404, 411, 
412 
403,411,417 
404, 412, 418 
CAGAATCATTCCAAATACmTATCATAGA 
CATC 
GAGAGATCTCATGACAGAGCAGCAGTGGA 
ATTTC 
GGCAGATCTCTATGCGAACATCCCAGTG 
GTTGGATCCTGCGAACATCCCAGTGACG 
417,418 
405, 406, 414, 
419, 420 
405, 406, 413, 
414, 419, 420 
413 
GAGCAGATCTATGACAGAGCAGCAGTGGA 
ATTTC 
GAACAAnTGATCACAAGATCCTGAATATA 
CC 
AATTCCTCTGATCATTATTrAGATnTAATT 
CCTG 
GAGAAAAATGATCAATCJCAAGATCCTGAAT 
ATACC 
GAGGTATATATTAATGTATCG 
GGGCrCTGCTGTGTGCTG 
ATGGGTCmTCTGCAGTCAC 
Figure I. Schematic representation of the site-directed mutagenesis of the P71 ORF. Shaded 
arrows indicate positions of PGR primer binding sites. The primer designations are given 
above or below the arrow and are described in Table 2. The open stars indicate the position 
of TGA codons. The closed stars indicate TGG codons. Fragment designations are shown 
above each fragment. The poiy-histidine sequence (hatched box) and promoter (P) are shown 
for pTrcHis constructs. 
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P71 ORF 
P71.1 FP71.S1 FP71.S2 
HP71.S1 RP71.S2 HP71.S3 
i PGR ampllty P71 tragments A, A X BandC 91 331 g 
304 572 Q 
541 937 
AB 
1 Gel purify PGR fragments and perform overlap extension 
91 572 
BC 
304 937 
P71.1 
 ^ AB 
91 575 
RP71.S2 
FP71.S1 
1 Gel purify PGR fragments and perform PGR to increase concentration 
B-C 
304 937 
HP71.S3 
ABC 
i 
1 
Gel purify PGR fragments and perform 
sverlap extension, creating fragnwnt 
ABC 
Gel purity ABC fragment and pertorm 
PGR to add SBmHI site, done fragment 
Into pTrcHis, generating plasmid 
PISM408 
ABC SamHI 
-• if 
I Amplify fragment D 
FM71.S3 
Gel purify and done into plSM408 to 
generate plasmid plSM409 1 P71^ 
SofflHI 
1878 
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Plasmid Constructions 
Plasmid constraction strategies were initially designed using the Gene Construction Kit 2 
software (Textco, Inc., N.H.). Cloning of DNA into various plasmids was accomplished 
following established protocols. The vectors used for constructing plasmids for expressing 
recombinant proteins were pTrcHis A and B (Table 1). Plasmids for use as genetic vaccines 
were constructed with pVR1012 and pVR1020 backbones. The digested vectors were routinely 
subjected to calf intestinal alkaUne phosphatase treatment to prevent self-ligation. Purification of 
each DNA fragment was performed by agarose gel electrophoresis followed by extraction from 
agarose slices using the QIAEX n gel extraction kit. Ligation mixtures contained 1:1 and 1:2 
molar ratios of vector to insert for smaller and larger inserts respectively. One unit of T4 DNA 
ligase was used per ligation reaction in a 10 |il volume that contained approximately 100 ng of 
vector DNA. Ligation mixtures were incubated overnight at 16°C prior to transformation. The 
orientation of cloned fragments was verified by restriction mapping or by PCR. Verification by 
PCR required the use of a vector-specific forward and an insert-specific reverse primer. DNA 
sequencing was done to verify the sequence or the reading frame wherever warranted. When 
necessary, clones were digested with restriction enzymes and the fragments analyzed by agarose 
gels to identify clones with fragments in the proper orientation. 
Construction of cloning vectors with Es sequences 
The complete open reading frame (ORF) of Es was amplified from plasmid pA using 
primers FlEs and RlEs as described above. The purified PCR fragment was digested with 
Bgia and cloned into the Bamiil site of plasmid pTrcHis B. The resulting plasmid, designated 
pISM403, contained Es encoding AUG start and UAG stop codons. 
Construction of plasmid pISM404 was identical to pISM403 except that primers FlEs and 
R2Es were used for amplification of Es. The resulting PCR fragment lacked a TAG stop codon 
encoding sequence but resulted in the reconstruction of the BamHl site at the 3' end of the 
gene. The PCR product was subjected to double digestion with BaniHL and Bg/n, and then 
cloned into the BamHL site of pTrcHis B. The resulting plasmid, pISM404, could be used in 
future cloning experiments to generate fusion proteins at the carboxy terminal end of Es with 
poly-histidine sequences to facilitate protein purification. 
The Es gene was also inserted into DNA vaccine vectors pVR1012 and pVR1020 as 
follows. The two plasmids, pVR1012 and pVR1020, differ in the presence of a tissue 
plasminogen activator (TPA) signal sequence in the plasmid pVR1020, which will result in the 
protein product being exported in vivo. Es was PCR amplified from pISM403 using primers 
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FlEs and RlEs, was digested with BglR and was then cloned into the BamlU site of plasmid 
pVR1012 to generate plasmid pISM411. Primers F2Es and RlEs were used to amplify the Es 
gene for cloning into pVR1020 to generate plasmid pISM417. The primer F2Es was designed 
to maintain the reading frame with the tissue plasminogen activator (TPA) sequences in 
pVR1020. To create vectors for producing Es protein fusions, similar constructs were made 
with a BamHl site downstream of Es. This was accomplished using different PGR primers, 
FlEs and R2Es to generate the pVR1012 derivative plasmid pISM412, and primers F2Es and 
R2Es to generate the pVR1020 derivative plasmid pISM418. Each of these plasmids contained 
a 3' BamHL site regenerated during the cloning process. 
Construction of P97 fusion plasmids 
The ORF of P97 was amplified from plasmid pMYC0161 template DNA using 
primers FMhp3 and RMhp3 as described above. The primers were designed so that P97 
would be in the correct reading frame with the poly-histidine sequence of pTrcHis. The PGR 
product was digested with BcH following manufacturer's guidelines and cloned into the 
BamlU. site of pTrcHis A. The resulting plasmids were screened by restriction digestion to 
identify a clone with P97 in the proper orientation (pISM405). Following induction in E. coli, 
the resulting P97 protein has a poly-histidine sequence to facilitate purification by metal 
chelate chromatography. 
Plasmid pISM406 was constructed by cloning the PGR product generated from plasmid 
pISM405 with primers FMhpB and RMhpS. The fragment was digested with Bc/I restriction 
enzyme and cloned into the BamVl site of pISM404. Restriction digests were used to identify 
clones with the P97 fragment in proper orientation. The resulting plasmid contains a fusion 
protein of Es with P97 in the pTrcHis plasmid background. 
The gene for P97 was cloned into pVR1012 by first generating a PGR product from 
pISM405 plasmid using primers FMhp4 and RMhp3. The PGR product was digested with BcH 
restriction enzyme and cloned into the BamlU. site of pVR1012 to generate plasmid pISM4I3. 
The FMhp4 primer incorporated an ATG start codon at the 5' end of P97 gene. The Es:P97 
fusion was constructed as follows. A PGR product generated from plasmid pMYG0161 using 
primers FMhp3 and RMhp3 was digested with BcH restriction enzyme and cloned into the 
Bamin. site of pISM412. This construct, designated pISM414, generates a fusion protein of Es 
withP97. 
The gene for P97 was cloned into pVR1020 by first generating a PGR product from 
pISM405 template DNA using primers FMhp3 and RMhpB. The PGR product was digested 
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with BcR. restriction enzyme and then cloned into the BamYS. site of pVR1020 generating 
plasmid pISM4l9. To construct the Es:P97 fusion in pVRI020, a PGR product was obtained 
using pISM405 template DNA and primers FMhp3 and RMhp3 primers. The fragment was 
digested with BcH restriction enzyme and cloned into the BamHL site of pISM418 to generate 
plasmid pISM420. 
Construction of plasmid pISM407 
Plasmid pISM2137 was excised from a recombinant Lambda 21AP H clone by M13 rescue. 
This plasmid contained a 4.9kb DNA fragment from the M. hyopneumoniae genome. The clone 
was identified by screening a genomic library with convalescent serum obtained from vaccinated 
and challenge-protected pigs (65). TnlOOO mutagenesis was performed on plasmid pISM2137 
to identify the open reading frame recognized by the antisera. An open reading frame encoding 
a 71-kilodalton protein, P71, was identified by analysis of the DNA sequence. The P71 open 
reading frame (ORF) was amplified by PGR with primers P71.1 and P71.2 using pISM2137 as 
the template. The primers included BglU. sites for cloning purposes. The PGR product was 
digested with BgUl and cloned into the BamHl site of pTrcHis A generating plasmid pISM407. 
Construction of plasmid derivatives containing altered P71 sequences 
Fragment ABC of P71 was obtained by overlap PCR as described above. This fragment 
contained TGG replacement triplets for TGA triplets at three of the four positions. In order to 
obtain sufficient quantities for cloning and insert appropriate cloning sites, a second PGR 
amplification was performed using primers P71.1 and RM71.S3 and the original ABC 
fragment as template. The resulting PGR product contained the mutated M71A 5' end fragment 
of P71 plus BamlU. and BglD. sites. The fragment was subjected to double digestion with 
BamiU. and BglR and cloned into SamHI-digested pTrcHis A creating plasmid pISM408. The 
3' end of P71 with an altered TGA triplet was cloned in similar fashion using the original ECR 
product described above with primers FM71.S3 and P71.2. The resulting PCR product was 
subjected to double digestion with BamHl and BglD. and cloned into ^omHI-digested pISM408 
plasmid resulting in plasmid pISM409. The primer FM71.S3 was so designed so as to 
maintain the reading frame. 
Additional derivatives of P71 were constructed as follows. The modified P71 ORF was 
amplified from pISM409 using primers P71.1 and P71.2, digested with fig/n restriction 
enzyme and then cloned into the BcpnHl site of pISM404. The resulting plasmid, pISM410, 
produces a fusion protein of Es and P71. 
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To generate P71 containing derivatives of the DNA vaccine vectors, the following 
experiments were performed. The PGR product generated from pISM409 using primers P71.4 
and P71.2 was digested with BglO. restriction enzyme and cloned into the Bam¥l site of 
pVR1012. This generated plasmid pISM415. The Es fusion derivative of pVR1012 was 
constructed by cloning the PGR product from a reaction with pISM409 template DNA and 
primers P7I.1 and P71.2 into plasmid pISM412. The PGR product required BglQ. digestion 
and was cloned into the BomHI site generating plasmid pISM416. Gomparable derivatives of 
pVR1020 were also constructed. The PGR product generated from pISM409 using primers 
P71.1 and P71.2 was cloned into the BamYQ. site of plasmid pVR1020 to generate plasmid 
pISM421 following flg/n restriction of the fragment. This required in-frame cloning with the 
TPA signal sequence present in the plasmid. The Es fiision with P71 was constructed in 
pVR1020 by cloning the same PGR fragment used in plasmid pISM421 construction into 
plasmid pISM418. This generated plasmid pISM422. 
E. coli Transformation 
E. coli cells were prepared for electroporation as follows. E. coli LE392 stock cultures were 
inoculated into 3-5 ml of LB broth followed by overnight growth under vigorous shaking. A 
1:500 dilution of the culture was subcultured into SOOml of 2X LB broth, and continued to 
incubate with shaking at 37°G until the culture reached an optical density between 0.5 and 0.7 at 
600nm, All other steps were carried out at 4°G. The cell culture was chilled using an ice water 
bath, and the cells were pelleted at 5000 x g (6000 rpm using pre-chilled JA-14 rotor in 
Beckman J2-21 centrifuge) for 10 min at4°G. The cell pellets were re-suspended in an equal 
volume of chilled sterile water, pelleted and washed a second time with half the volume of 
chilled sterile water. After the second wash, the cell pellets were re-suspended in half the volume 
of chilled sterile 10% glycerol and incubated at 4°G for 10 min. The cells were pelleted once 
again and re-suspended in 0.002 to 0.003 original culture volume of sterile, cold 10% glycerol 
and dispensed in 70 pi aliquots in 0.5 ml eppendorf tubes. The aliquots of cells were snap-
frozen in a dry ice-ethanol bath prior for storage at -70°C. Electro-competent E. coli cells 
generally gave a transformation frequency of approximately 2-5 x 10^ transformants per pg of 
pKS plasmid DNA for 3 to 6 months. 
Electro-competent cells were thawed on ice, and 60 fjl of E coli competent cells were used 
in each transformation reaction with 5-20 ng of plasmid DNA. The plasmid DNA was mixed 
with electro-competent cells, transferred to chilled 0.2 cm electroporation cuvettes and pulsed 
once at 2.5 kV of charging voltage and 129 Ohms resistance using an Electro Gell Manipulator 
(Model EGM 600, BTX, San Diego, Galif.). These conditions produced an estimated field 
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strength of 12.5 - 14.4 kV/cm. A time constant above 5 msec was generally achieved at this 
setting with DNA samples that had little salt or ions. The pulsed cell mixtures were diluted into 
1 ml of SOC media and then incubated at 37°C for one h prior to plating the transformation 
mixture onto selective media. 
Primer Synthesis and DNA Sequencing 
The Iowa State University DNA Facility synthesized all primers and performed all DNA 
sequencing. Primers (Table 2) were designed using the OUgo 5 software (National Biosciences, 
Inc., Plymouth, Minn.) and synthesized in a DNA/RNA Synthesizer (Model 399, Applied 
Biosystems, The Perkin-Elmer Corporation, Norwalk, Connecticut). DNA sequencing was 
performed using cycle sequencing protocols and an automated DNA sequencer (Model 373 or 
377, Applied Biosystems, The Peridn-Elmer Corporation, Norwalk, Conn.). The deduced 
sequences were edited and assembled using a combination of Factura, AutoAssembler and 
Sequence Navigator (Applied Biosystems, The Perkin-Ehner Corporation, Norwalk, Conn.) 
software applications. The DNA sequence analysis was performed with Mac Vector 6.0 
software (Eastern Kodak Company, Rochester, N.Y.). 
Plasmid Preparations 
Plasmid DNA for general purposes was isolated from E. coli according to the method of 
Bimboim (II) with slight modifications. The crude plasmid preparation in TE buffer was 
incubated at 6S°C for IS min with an equal volume of lithium chloride solution (5 M lithium 
chloride, 0.05 M MOPS, pH 8.0) and centriftiged to remove most of the contaminating 
precipitated proteins. The DNA was precipitated with two volumes of ethanol and the pellet 
washed with 70% ethanol. For sequencing, plasmid DNAs were prepared using Qiagen midi-
plasmid purification kit (QIAGEN Inc., Chatsworth, Calif.) according to the manufacturer's 
instructions with minor modifications. The DNA was precipitated with isopropanol and pelleted 
in eppendorf mbes in a microftige to prevent the loss of DNA. Air-dried pellets were dissolved 
in sterile H2O or Tris buffer (10 mM Tris-HCI; pH 8.0). For genetic vaccinations, plasmid 
DNA was prepared using the Qiagen EndoFree Plasmid Giga Kit (QIAGEN Inc., Chatsworth, 
Calif.) according to the manufacturer's instmctions with minor modifications. Prior to QIAfilter 
cartridge filtration, the alkaline lysates were initially centrifuged at 10,000 x g for 15 min using 
the JA-14 rotor in Beckman high speed centrifuge at room temperature to remove the larger 
particulate cell debris. This additional step helped to prevent clogging of the filter assembly. The 
protocol also incorporated a buffer treatment that removed the endotoxin present in the plasmid 
preparations. The endotoxin free plasmid DNA thus obtained was dissolved in normal saline by 
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overnight suspension at 4°C. The DNA concentration was estimated by either fluorometric or 
spectrophotometric means. The DNA fluorometer (Model TKO 100, Hoefer Scientific 
Instrument, San Francisco, Cahf.) required the use of the fluorochrome Hoechst 33258 to 
measure the amount of DNA in the sample. The Molecular Biology Assistant 2000 (The 
Perkin-Elmer Corporation, Norwalk, Conn.) measured DNA concentrations based on its 
absorbance at 260 nm. 
Polymerase Chain Reactions 
In all cases, except for the purpose of site directed mutagenesis, Taq DNA polymerase 
(GIBCO-BRL, Sigma and Qiagen) was used for PCR reactions. Standard conditions were 
followed. The PCR mixtures always contained IX PCR buffer provided by the company for 
their respective polymerases. In addition, 200 ^iM of dNTPs and 0.5 ^M of each of the primers 
were added for each reaction, and the reaction volume was kept constant at 100 pi. For 
verification of orientation of cloned fragments, PCR was conducted in 50 pi volumes. 
Generally, 1 mM of magnesium chloride was added to PCR reactions, but the PCR reaction 
mixtures for Mhyo gene fragments required higher levels, between 1.5 and 3 mM of 
magnesium ions. The Es gene PCR ampUflcation cycles consisted of 5 cycles at 94°C for 1 
min, 62°C for 0.5 min and 72°C for 2 min. This was followed by an incubation step of 94°C for 
3 min, and then 25 cycles of 94°C for 1 min, and 70°C for 2.5 min followed by a 10 min 
incubation step at 72°C. The P97 PCR amplification cycles consisted of 5 cycles at 94°C for 1 
min, 45°C for 30 sec and 72°C for 2 min followed by an incubation step at 94°C for 5 min. This 
was followed by 25 cycles of 94°C for 1 min, 52°C for 30 sec and 72°C for 3 min and ended 
with an incubation step for 10 min at 72°C. The P97 reaction mixtures also had 2 mM of 
magnesium chloride. 
Induction of Bacterial Cultures 
The pTrcHis plasmid constructs were transformed into E. coli TOP 10 cells for efficient 
expression of recombinant proteins. Individual colonies from freshly streaked plates were 
inoculated into SB media (32 g tryptone, 20 g yeast extract, 5 g NaQ per liter) containing 100 
|jg ampicillin per ml and incubated at 37°C in floor shaker for 6 hrs. It was subcultured into a 
lOOX volume of SB media containing ampicillin and incubated at 37°C with vigorous shaking 
until the ODggo was approximately 0.6. At that point, the incubating temperature was lowered to 
30°C. IPTG and phenyl methyl sulfonyl fluroide were added to a final concentration of ImM 
and 0.05 mM, respectively. The bacterial culture was induced for 6 to 8 hrs, and then the cells 
were pelleted at 5(X)0 x g for 10 min. at 4°C and stored frozen at -20°C after decanting. 
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Recombinant Protein Purification 
The mduced cell pellet was thawed and re-suspended in lysis buffer (20 mM Tris, 100 mM 
NaCl, 1 mg per oil lysozyme; pH 8.0). The suspension was incubated at room temperature for 
30 min and subjected to two &eeze-thaw cycles to lyse the ceils using dry ice/ethanol bath and a 
50°C water bath. The DNA was sheared by passing the sample several times through an 18G 
needle. The sample was then centrifuged at 12,000 x g for 20 min. at 4°C to pellet the insoluble 
material. The supernatant was transferred to another clean tube, and the pH checked again to be 
around 8.0. Ten ml of Talon metal affinity resin (CLONTECH Laboratories, Inc., Palo Alto, 
Calif.) was washed with the wash buffer (20 mM Tris, 100 mM NaCl; pH 8.0) and was added 
to the supernatant obtained from one liter of cells in a 50 ml centrifuge tube. The suspension 
was then rocked at room temperature for I to 2 hrs. The suspension was centrifuged at 700 x g 
for 2 min to pellet the resin, and the supernatant was decanted. The resin with bound protein 
was washed first with wash buffer, followed by 5,10 IS and 20 mM imidazole containing wash 
buffers. Each washing step consisted of re-suspension of the resin in the buffer followed by 
rocking for 10 min. The resin was pelleted after each step by centrifuging at 700 x ^ for 2 min. 
The recombinant protein was then eluted after the washes using suitable volumes of the wash 
buffer containing 500 mM imidazole. The eluent was dialyzed against PBS two times and then 
against deionized water using SPECTRA/POR 3 dialysis membrane (SPECTRUM, Houston, 
Tex.) with a molecular weight cut-off of 3,500 daltons at 4°C. The dialyzed material was then 
freeze-dried (Multi-dry system, FTS Systems, Inc., Stone Ridge, N.Y.) to concentrate the 
protein. The purified and freeze dried proteins were then dissolved in water and stored frozen in 
aliquots at -20°C. Protein concentration was estimated using the Bio-Rad protein micro-assay 
procedure (BIO-RAD laboratories, Richmond, Calif.). The absorbent readings were taken using 
a microplate reader (Model no: EL 310 by BIO-TEK Instruments, Inc., Winooski, Vt.) at 595 
nm. Protein concentrations were estimated by plotting OD at 595 nm on a curve generated 
using protein standards. Bovine serum albumin was used as the reference protein for preparing 
the standard curve. 
Immunoblot Analysis 
Immunoblotting was performed according to the method of Towbin (98). Proteins were 
resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in 
duplicate using the Bio-Rad min-gel system. One of the gels was stained with Coomassie 
Brilliant Blue (R250) and the other transferred to nitrocellulose membranes (Midwest Scientific, 
St. Louis, MO.) using either the Transphor Electrophoresis Unit (TE series, Hoefer Scientific 
Instrument, I'iscataway, N.J.) or the Bio-Rad mini-blotter system. Transfer was accon^lished 
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using chilled transfer buffer at 100 volts constant voltage for one h at 4°C. The membranes were 
blocked with TS-Tween buffer (0.01 M Tris-0.140 NaCl-0.01 Tween 20) plus 5% powdered 
sifim milk for one h and washed 3 times with TS-Tween for 15 min each. The blots were 
incubated with Anti-Xpress antibodies (Invitrogen Corporation, San Diego, Calif.) diluted 
1:5000 in TS-Tween buffer and rocked overnight at room temperature. The membranes were 
then washed as described above, and then incubated with alkaline phosphatase conjugated anti-
mouse IgG secondary antibody diluted in TS-Tween for two hrs. After washing, the blots were 
developed with AP substrate (Naphthol 0.03 g-Fast Red 0.06 g in 60 mis of 20 mM Tris-HCl; 
pH 8.0). After color development, the reaction was halted by decanting the substrate, and the 
membranes were rinsed with a large volume of H2O. The membranes were then air-dried. 
Mice 
Mycoplasma ftee female Balb/c mice at 6 to 8 weeks of age purchased from Jackson 
Laboratories (Bar Harbor, Maine) were used in this study. Groups of 6 mice were housed in 
individual cages at the Laboratory Animal Resource Facility, Iowa State University. The mice 
were kept under observation for one week in the unit prior to beginning the experiment to 
acclimate them. All animal studies were conducted according to the guidelines of the Iowa State 
University Committee on Animal Care and Use. 
Vaccinations 
Groups of 6 mice were immunized with purified proteins or with plasmid DNAs according 
to the schedule shown in Tables 3 and 4. For the protein studies, mice were vaccinated with 10 
|ig of the Es fusion protein (Es-P97 or Es-P71), 9 ng of the protein alone (P97 or P71) or 1 ng 
of Es recombinant protein. The antigens were suspended in saline and then mixed using two 
syringes connected by a bridge needle with IFA in a 1:1 ratio. The trials with P71 recombinant 
proteins did not include adjuvant. The protein concentration was adjusted to provide an 
individual dose in 100 pi and was administered intramuscularly into the thigh muscle. The 
control mice were injected with either normal saline for P71 experiments or with saline mixed 
with IFA for P97 experiments. For genetic immunization trials, 100 fig of endotoxin free 
plasmids in normal saline were injected intramuscularly into the thigh muscle of mice primed 
two days earlier with 100 pi of 0.25% Bupivacaine. The booster dose also followed another 
bupivacaine priming. The control mice were vaccinated with the vector plasmids alone. For P97, 
the genetic constructs with the pVR1012 backbone were the only plasmids tested while for P71, 
the genetic constructs with both pVRI012 and pVR1020 backbones were tested. 
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Table 3. Immunization schedule for protein trials 
DAY EVENT 
Day 0 Vaccination 
Day 14 Boost 
Day 25 Sacrifice (3 per group) 
Day 35 Sacrifice (3 per group) 
Table 4. Immunization schedule for genetic immunization trials. 
DAY EVENT 
Day "2 Bupivacaine injection 
Day 0 Vaccination 
Day 19 Bupivacaine second injection 
Day 21 Boost 
Day 32 Sacrifice (3 per group) 
Day 42 Sacrifice (3 per group) 
At necropsy, the mice were euthanized using COj and exsanquinated by cardiac puncture. 
The blood was transferred into eppendorf tubes and allowed to clot at 4°C. Serum was collected 
the next day by centrifugation and transferred to another eppendorf tube. It was stored at 
-20°C. Spleens were removed aseptically using sterile instruments and transferred to a petri 
dish containing 5 ml of RPMI medium. 
Splenocyte Isolation and Culture 
Each excised spleen was dispersed into a single cell suspension and the cells were washed 
once in basal RPMI medium. The lymphocytes were counted using a Coulter particle counter 
(Model Zl, Coulter Corporation, Miami, Ha.). The lytic reagent ZAP-OGLOBIN n (Coulter 
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Corporation) was added for stromalysing of the contaminating RBCs in the IsoFlow sheath 
fluid provided by the manufacturer. Cell cultures were set up in complete RPMI and incubated 
at 37°C in 5% CO^ under relatively high humidity. 
For cytokine analysis, cell cultures were set up in 48 well tissue culture clusters (Costar, 
Cambridge, Mass.) with 5 million cells/well incubated with 10 ^g of the antigen of interest. The 
negative control wells had cells alone in complete RPMI while the positive control wells had the 
cells stimulated with Concanavalin A. The supernatant was collected after 72 hrs of incubation 
by centrifiigation and stored frozen at -70°C until analyzed. 
Blastogenesis 
To assess blastogenic responses, cell cultures were set up as described above. Five hundred 
thousand lymphocytes were incubated with 2 |iig or 0.2 (ig of antigen in a 200-jil volume in 
wells of flat bottom 96 well tissue culture microtiter plates (Costar Corporation, Cambridge, 
Mass.). The negative control wells had no antigen while the positive control wells had 
Concanavalin A fraction IV at 1 pg per ml. In some experiments, Concanavalin A fraction V 
was used. All the treatments were done in triplicate and the controls were set up in separate 
plates. Each of the wells were pulsed with 0.5 pCi of methyl [H^] thymidine (specific activity of 
6.7 Ci mmole ', Amersham Life Science, Arlington Heights, HI.) in 10 ^1 of RPMI medium after 
4 and 2 days of incubation of sample and control plates, respectively. The cells were harvested 
onto glass fiber filters using a PHD cell harvester (Cambridge Technology, Cambridge, Mass.) 
18 h after pulsing. The incorporated radioactivity was measured after the addition of Scintiverse 
fluid (Fischer Scientific, Fair Lawn, N.J.) using the Liquid Scintillation Analyzer (Model Tri-
Carb 15(X), Packard Instrument Company, Downers Grove, HI.). The stimulation indices were 
calculated by dividing the average counts per minute of the stimulated cells by the average 
counts per minute of non-stimulated cells in triplicate wells. 
Estimation of Antigen-Specific Antibody Responses 
An ELISA was employed to measure antigen specific IgGl and IgG2a antibody responses. 
Immulon 2™ microtiter plates (Coming, Park Ridge, 111.) were coated with 0.2 jig /well of the 
protein diluted in coating buffer (2.93 g sodium bicarbonate, 1.5 g sodium carbonate, 0.2 g 
sodium azide per liter, pH 9.5) by overnight incubation at 4°C. The coated plates were blocked 
with 1% gelatin in PBS buffer (8g NaCl, 1.5g Na2HP04,0.2 g KH2PO4,0.2 g KQ per liter, pH 
7.4) for one h. Further, the serum samples (1:100) were added to appropriate wells and 
incubated at 37°C for 1.5 hrs. Afterwards, the plates were incubated with isotype specific 
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alkaline phosphatase conjugated goat anti-mouse IgGl or IgG2a (1:1000) (Southern 
Biotechnology Associates, Inc., Birmingham, Ala.) for one h at 37°C. The plates were washed 
with PBS containing 0.5% Tween 20 (Sigma, St. Louis, Mo.) in between every step, and then 
developed using alkaline phosphatase substrate (Sigma 104, Sigma, St. Louis, Mo.) (Img per 
ml) in substrate buffer (97 ml diethanolamine, 100 mg MgCl2*6H20,0.2 g sodium azide per 
liter; pH 9.8). The results were read at 405 nm and presented as the average O.D. values of 
duplicate wells. 
Estimation of Antigen-Specific IFN-yand IL-10 
The antigen specific IFN-yand IL-10 levels in culture supematants were measured by a 
sandwich ELISA using a modified cytokine ELISA protocol as suggested by PharMingen, (San 
Diego, Calif.). Cell cultures were incubated with media alone (negative control), ConA (positive 
control) or one of the proteins (Es, P97, P71, Es-P97 or Es-P71) as described previously. 
Briefly, Immulon 2™ 96 well plates were coated with capture antibody (rat Mab XMG 1.2 for 
IFN-y, rat Mab JES5-2A5 for IL-10, PharMingen) at 2 Mg per ml in coating buffer overnight at 
4°C; blocked with 1% gelatin for one h at 37°C, and then incubated with 100 pi of culture 
supematant diluted either 1:2 or 1:4 in basal RPMI for one h at 37°C. For IFN-y estimation, the 
plates were then incubated with 100 pi of a 1:20(X) dilution of rabbit anti-mouse IFN-y 
antibodies (gift from Dr. Randy Sacco at NADC, Ames, Iowa) followed by incubation with 100 
pi of alkaline phosphatase conjugated donkey anti-rabbit Ig (Jackson, West Grove, Penn.). For 
IL-10 estimation, plates were incubated with biotinylated rat anti-mouse IL-10 (SXC-1) 
(PharMingen) at 1:2000 dilution followed by alkaline phosphatase conjugated strepavidin 
(Southem Biotechnology Associates). The plates were washed with PBS-Tween after each 
incubation step. The plates were developed by the addition of alkaline phosphatase substrate 
(Sigma 104) and the developed color quantified by measuring the OD at 405 nm. The 
concentrations of IFN-y and IL-10 in the culture supematants were estimated from the standard 
curves generated using rIFN-y and rIL-10 respectively for the average of duplicate wells. 
Statistical Analysis 
Statistical evaluations were performed by one-way analysis of variance or Mann Whimey 
test using InStat 2.0 (GraphPad Software, San Diego, Calif.). 
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RESULTS 
Piasmid Constructions 
Cloning and analysis of P71 gene sequences 
The screening of a M. hyopneimoniae XZAPII genomic library with convalescent, 
challenge-protected pig sera resulted in the identification of several positive phage plaques (65). 
Several of these were selected for further study. The recombinant plasmids were excised from 
the phage using the M13 excision process according to the manufacturer's directions 
(Stratagene), and the cloned fragments were restriction site mapped. Several of the clones 
overlapped a single chromosomal region, and these were selected for further study (Fig. 2), One 
of the overlapping clones, pISM2137, was subjected to InlOOO mutagenesis to identify the 
ORF coding for the antigenic epitope recognized by the pig sera. Figure 2 shows the restriction 
map of the overlapping clones including pISM2137 and the InlOOO inserts used for DNA 
sequence analysis. DNA sequence analysis was performed on the sequence using the Iv^lOOO 
inserts as priming sites. The single ORF within pISM2137 codes for a 71-kDa protein that has 
been designated P71. The P71 DNA sequence is shown in Figure 3. Analysis of the DNA 
sequence revealed the presence of three TGA triplets at positions 322,553, and 925 (Fig. 3), 
The gene was found to be homologous with a 65 kDa protein gene identified previously by 
Wise and co-workers (56). The Genbank accession number for P71 is AFO15665. 
Site-directed mutagenesis of P71 
A PCR-based protocol for site-directed mutagenesis of the P71 structural gene was chosen 
because preliminary studies with other mutagenesis methods proved unsatisfactory. Figure 1 
depicts the overall strategy of the process. Each step required the optimization of the PCR 
reaction conditions including extension temperature, MgClj concentrations, etc. Materials and 
Methods give the optimized conditions for each step. PCR products were mixed and extension 
reactions performed to obtain fragments predicted to encode multiple modified UGA codons. 
The gene was cloned in two steps. The first step was insertion of the 5' end of the gene 
encoding all three modified UGA codons into pTrcHis to generate piasmid pISM408. A 
BamVl cloning site was placed downstream of the position corresponding to the third UGA 
codon by altering two base pairs of the sequence in the final PCR reaction resulting in a two 
amino acid change in the polypeptide sequence. An identical change was incorporated into the 
3' portion of the gene during the PCR reaction (Fig. 1). This 3' firagment was then cloned into 
pISM408 to generate piasmid pISM409, which contained the P71 coding sequence (minus the 
immediate 5' membrane-spanning domain represented by base pairs 1 - 92). 
34 
M P C H E E C 
I I U i 1 
2151 ^ A A AAi A  A  i  A  A  ^  
+  + -  - -  - -  +  • ( -  +  
2157 C/H B 
2160 B C/H 
2144 B C/H 
2137 C/H B 
2137A 
P71 
PRPP synthetase P115 Homologue 
B " I I I I 
P71 
—X—I na— 
Figure 2. Restriction map of P71 overlapping clones and location of TniOOO inserts. A. Shown 
are the restriction maps of the five overlapping recombinant clones recognized by convalescent, 
challenge-protected swine sera. The pISM plasmid designations are given on the left. Filled 
triangles represent the locations of TniOOO inserts. In pISM2151, the TnlOOO insertions are 
accompanied by immunoreactivi^ reactivity data (+ or -) as described in the text. Plasmid 
pISM2137A was obtained by deleting the /frndlQ fragment of pISM2137, The restriction sites 
at the ends of the fragment represent sites in the multiple cloning site of the cloning vector. 
Restriction enzymes: B, BomHI; C, Clal, E, EcoRI; H, HmdSR. E* represents an EcoRI site 
regenerated during the initial cloning. Also shown are genes with homologies to known proteins 
located upstream and down stream of P71. The direction of transcription is given by the single 
arrows. B. Location ofTnlOOO inserts generated in pISM2137A to facilitate sequencing. The 
size marker is given in kb. 
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AAGCTTCaGAAAATTACMAAAAAATTCATITrcCAAAAACGCTTTTAGCTITTAITAAAGGGCCCAAAGTTTTTAATGAA 81 
GTTCAAAATTGTAAAAATTGTAATTATAAAATCATTAAAGTTAATAATAATATAAATAAAAAAATTTTTATCGCATTTAAA 162 
CAAGa'X'TCTTAATAATITTCAATTTrAATTTAGflMATATAAAAATCTOyX'TaAriTITATATAftTTTTTTflACLTrm'i' 243 
'm'mTm'm'm'NaGGAATATGGTAAAAinTAGTCCATCTATCAAAAATATAGAAAAGGAAAAATTATGAAGAAAAA 324 
M K K K> 
AGCaAGAAAATTCTTAAGACTAACTTCX3CTTACACTAGCGCCTTTTTCGGTTrTTACCACTCrrATTTC»GCTGGATGm 405 
A R K F L R L T S L T L A P F S V F T T L I S A G C L >  
GCAAAAAAATTCTTTGCTITCAGAAGTAAATTATTTAGCACTAGGCGATTCGCTAACAGCTGGATTTAATGAAGAAACATA 486 
Q K N S L L S E V N Y L A L G D S L T A G F N E E T Y >  
CaSTGATTTTCAAGGTACTTTAGATAAAGATGGTAATTTAAGCGtnakAlCTTATCCTGCTTATTTTGCTTATTATCTACA 567 
R D F Q G T L D K D G N L S G Q S Y P A Y F A Y Y L Q >  
AAAACTTAATAAGAATKayOTGTnXOTATGATAATTTGGCAATTTCTGGGACAACAACAGAAAACTGACTTTACCTTCT 648 
K L N K N S r , V S Y D N I . A I S G T T T E N W L Y L L >  
TAATCCAACCAAATATCCAAATGGAAAAATGAGCGATAATCCTTTAGTTACAAACTATTCAGGAAATGAAAAATATAATGA 729 
N P T K Y P N G K M S D N P L V T N Y S G N E K Y N E >  
AATAGGTTCTGTTTTTGGTGATTTTAATAAGGATTCCTATCCTGGTTTAGTCGAAAAAGTTAAGAAAGCAAACCTTTTGAC 810 
I G S V F G D F N K D S Y P G L V E K V K K A N L L T >  
AATGTCAGTGGGAGCTAATGATCCTTTTTTAGCAATTTTTAATGAATTTAAAAAATGAGCAAGTATAATAAAACCAAAATC 891 
M S V G A N D P F L A I F N E F K K W A S I I K P K S >  
AGAGGAAGCAAAAAAATTACTAGATCCAAATGAAAGAGCGAATTTCCTGGCAGAAAAAGGAATGCTTTTAAAAGCXSGAAGT 972 
E E A K K L L D P N E R A N F L A E K G M L L K A E V >  
CAATAAAAAAATTGAAGAAATAAACACAAATCTTGATAATTTAATTAAAGAAITTAAAGGCGCTTAATCCAAAATTAAGTAT 1053 
N K K I E E I N T N L D N L I K E L K A L N P K L S I >  
AAATTTAATTGGATATAAAITXKCAAATTCCGGTTTTATTAAGATTTTAAAATATCTTTTATATACTTATGCAAAAATTGA 1134 
N L r G Y K L P N S G F r K I L K Y L L Y T Y A K I E >  
AACGGACTTTATCAATGAAATTCCCGAAAAAATTAACAAAATTATTCGTGAAAGCGCCATTAAAAATAAGGTAAATTATAT 1215 
T D F I N E I P E K I N K I I R E S A I K N K V N Y I >  
TGATGTCTATGATAAAAGTATTTGAAATGA3TCK3ATAAAAATTTAATGGCGAAAAAIITITOACTTCCaCCCTTCAATTCA 1296 
D V Y D K S I W N D S D K N L M A K N F D F H P S I Q >  
Figure 3. Nucleotide and amino acid sequence of P71 of M. hyopneumoniae strain 232. 
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AGGTrATAAAAAMTTGCTCACCAACTTrTGTTAAAACrTGACCAAGAAGAAAAAGATGA.TTCrAATGCrGAAGAGCTAAA 1377 
G Y K K I A H Q L L L K L D Q E E K D D S N A E E L I O  
AAATACTACAAATTTCGATGATTTTGATGAGAATAAACCGACCTATTCCAAAGTTATTGACCTAAGTGTTTTTGCAAAATC 1458 
N T T N F D D F D E N K P T Y S K V I D L S V P A K S >  
AAATAAAGAATTTCTTGAAAAATTAAACGAAAATAAGCAAACTAGTGAATTTATTGCTCAAAAATCCACTTTTGACACCGA 1539 
N K E F L E K L N E N K Q T S E F I A Q K S T F D T D >  
TCAAGAAGCTGCAATCAAAGACGACAAACGC»CTTITGGAAATATAGTTCGAGAAATTGTATCTTTACCAATCTTCGATAA 1620 
Q E A A I K D D K R T F G N I V R E I V S L P I F D N >  
TTTTGATrTTAGAGAGTTAATACCTGTTAAAAATCamTGTAAAflGCAATTATTAACAGCTATTTAGGGAAACCAGCTGG 1701 
F D F R E L I P V K N P F V K A I I N S Y L G K P A O  
TTCTCTTATAAAAGATATCGAACAACTCGAAAATAAAGTGAAAGATTACGCAAGACCTAATATCAAGATTTTCGATACAAT 1782 
S L I K D I E Q L E N K V K D y A R P N I K I F D T I >  
TATTGACTCATTCATMGAAAAATGGTAGCATTTm"GCrcAATTAAACACTGATCAAGAAATAAAAGAATTCAAAATGTC 1863 
I D S F I R K M V A F F A E L N T D Q E I K E F K M S >  
ACCrcAAATACTATTTCTGACACTAAGAAATGCAATACTAAGTCCATTTGATTTAACTAAATTAAAAGACAGTGCTACATT 1944 
P Q I L F L T I i R N A I L S P F D L T K L K D S A T F >  
TAAAATTTTAATGAATCTCAAACCAGAACAAATATTAACTTTACTAGGCCTAAGTAAAACCCCTTCAGTTCCTAAACCTGA 2025 
K I L M N L K P E Q I L T L L G L S K T P S V P K P E >  
AAAACCAAAAGATCAAAGTrCGAAGCCACAAACAGATACTTCTAGTCAAAAACAAGAAAGCGGAACAAGTTCAACAGATTC 2106 
K P K D Q S S K P Q T D T S S Q K Q E S G T S S T D S >  
AACAAAAGCTACAACTGAAAACC^AAAACCGGCTGAGCAAACAGATTCTTCTGAGCAATCAAGTACCGAGCCTAAATCAAA 2187 
T K A T T E N Q K P A E Q T D S S E Q S S T E P K S N >  
CTAATTTTTTAATAACTTATAATTATAAAAAACCTAAACTTATTTCAGTITAGGTTTTTATTTTCTAATTTGAAATTAGAA 2268 
ATATATAAGGAAAATTTTAGTATTTCTGACTGTGAAATTATGAflGTrAATAAAAATTGAflATTGAAGGTrTTAAATCCTTr 2430 
GCCGAATCTGTAASTATTAAATTTGATGGTTa^TTGTKXjAATAATTGGTCCAAATGGCTCTGGAAAATCTAATATAAAT 2511 
GATGCAATTAAATGAGTmAGGCGAAAAATCAGTTAAACAATTACGCGGCCAAAATATGGATGATGTCATTTTTGCTGGC 2592 
TCAAAAACAGTTATGCCTGTTAATAAMCGATGGTAAAACTGACATrTTTAGATGAAACTCGTGAASATAGTGCGCAAATr 2673 
TTTACAATTTCaX3AGTrATCAAAAGflGGACAAGGAACTAATGAATATTTTTATAATGATCAATTA(3TTCGCTATAAAGAT 2754 
ATTAGAAATTTAGCAATIXaflGCCGGAATTTCa^GTCTrcACTTGCAMTATTTCCCAAGGAACGATTTCTGAAATCGCC 2835 
GAA1CAAGCC(7IX3AACAACGAAAACAAGTAATCGM3GAAGT(X3CCGGAACTGCAAAATATAAAATTCCTGCAGCXXX3GGGG 2916 
ATC 
Figure 3 (Continued). 
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Construction of Es-containing plasmids 
The complete ORF of Es was cloned into plasmids pTrcHis, pVR1012 and pVR1020 (Fig. 
4). The inserts were generated by PCR amplification of the Es ORF present in plasmid pA 
using primers FlEs, RlEs, F2Es, and R2Es (Table 2). Plasmid pISM403 was used to produce 
poly-histidine tagged Es protein for purification purposes. Plasmids pISM411 and pISM417 
were Es controls in genetic immunization experiments. To generate the intermediate fusion 
protein constructs (pISM404, pISM412 and pISM418), the stop codon was removed from the 
reverse primer R2Es used for the generation of the Es inserts. Necessary changes in the 
forward primer were incorporated to generate an in-frame protein sequence at the N terminus 
with the histidine tag of cloning vector pTrcHis or with the tissue plasminogen activator signal 
of cloning vector pVR1020 that aids in secretion of the protein from mammalian cells. Qoning 
of the flg/n-digested PCR fragments into the flamHI-digested plasmids resulted in the loss of 
the BamHL restriction sites. Cloning of the double-digested BamYQ. and BgUl PCR insert 
fragments required for generating the intermediate fusion constructs resulted in the regeneration 
of the BamVl site at the 5' end of the insert. This site was then used to clone the P97 and P71 
PCR products to generate fusion proteins. The Es plasmid constructs except for pISM403 were 
transformed into LE392. Plasmid pISM403 was transformed into TOP 10 cells for protein 
expression. 
Construction of P97*containing plasmids 
Plasmids containing the P97 gene sequence were cloned using the P97 gene sequence from 
plasmid pMYCO obtained from Kendall King. It contained the P97 gene sequence minus the 
amino terminus membrane-spanning domain. The gene sequence also had been altered to 
remove the UGA codons encoding the original sequence. Primers FMhp3 and RMhp3 were 
used to generate a 3013 bp fragment that was digested with BcH, purified and cloned into 
pTrcHis to generate plasmid pISM40S (Fig. S). This plasmid was used to obtain purified P97 
protein for the immunization studies. Plasmid pISM406 was generated by cloning a PCR 
fragment containing the P97 coding region into the BomHI site of plasmid pISM404. The PCR 
fragment was generated from plasmid pISM40S using primers FMhp3 and RMhp3. This same 
fragment was used to generate plasmids pISM414, pISM419 and pISM420 by cloning into the 
Bam¥l site of plasmids pISM412, pVR1020 and pISM418, respectively. Plasmid pISM413 
was generated by cloning a PCR product generated from plasmid pISM40S using primers 
FMhp4 and RMhp3. This product included an ATG codon to initiate translation in vivo. The 
product was inserted into the BamW. site following digestion with BcH. Plasmids pISM406, 
pISM414 and pISM420 resulted in fusion proteins of Es and P97. 
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Figuie 4. Restriction maps of the Es-containing piasmids. Shown are the restriction site maps 
of piasmids containing only Es gene sequences. The plasmid ISM numbers are shown on the 
left. Relevant restriction sites are shown. The black arrows indicate antibiotic resistance 
markers; white arrows, lacP sequences; white hatched arrows, tpa sequences; and stipled 
anows, Es sequences. 
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Figure 5. Restriction maps of plasmids containing P97 gene sequences. Shown are the 
restriction site maps of plasmids containing P97 gene sequences. The piasmid ISM numbers 
are shown on the left. Relevant restriction sites are shown. The gray arrows indicate P97 
sequences; black arrows, antibiotic resistance markers; white arrows, lacP sequences; white 
hatched arrows, tpa sequences; and white batched bars, Es sequences. 
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Construction of P71-containing plasmids 
Plasmid pISM2137A contained the complete copy of P71 on a 2,919 bp fragment (Figs. 2 
and 3). Plasmid pISM2137A was used as template in a PCR reaction with primers P71.1 and 
P71.2. The resulting fragment was digested with BglD. and cloned into pTrcHis to generate 
plasmid pISM407 (Fig. 6). This plasmid was used as a template for the site-directed 
mutagenesis experiments. Constmction of plasmids pISM408 and pISM409 are described 
above. Plasmid pISM409 was used to purify recombinant P71 protein and as a PCR template 
for fiirther cloning of P7l gene sequences usmg primers P71.1 and P71.2. The PCR fragment 
represents nucleotides 90 - 1,878 of the modified P71 gene sequence. The first 89 nucleotides 
contained the signal sequence, membrane spanning domain and Upoprotein modification site, 
which could interfere with purification or stability of the recombinant protein. The modified 
sequence encoded the three UGA codons modified to UGG to prevent premature translation 
termination. The fig/H-digested fragment was cloned into pISM404, pISM412, pVR1020, and 
pISM418 generating plasmids pISM410, pISM416, pISM421 and pISM422, respectively (Fig. 
6). Plasmid pISM415 was generated from a PCR fragment using primers P71.4 and P71.2 to 
add an ATG start codon. The parent plasmid was pVR1012. 
Protein Purification 
The first step in protein purification using the poly-histidine tag and metal chelate 
chromatography involved standardization of the culture induction kinetics. This included 
examination of the growth media (LB, 2XYT, super broth), length of induction, incubation 
temperature, and concentration of IPTG. Using LB media, cells were induced for 5 h at 37°C, 
and samples taken at 1-h intervals. The yield was low in each case as determined by SDS-
PAGE (data not shown). Both 2XYT and super broth gave consistently higher yields. When 
incubated at 37°C following induction, the yield of purified product seemed low even after 5 hrs 
of induction. When the induction temperature was reduced to 30°C and the time of induction 
increased to 6-8 hrs, the yields were consistently higher. Various concentrations of IPTG were 
tested (0.1 mM, 1 mM, 5 mM and 10 mM), and the highest induction occurred with the higher 
concentrations of IPTG (5 and 10 mM) (data not shown). 
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Figure 6. Restriction maps of plasmids containing P71 gene sequences. Shown are the 
restriction site maps of plasmids containing P71 gene sequences. The plasmid ISM numbers 
are shown on the left. Relevant restriction sites are shown. The gray arrows indicate P71 
sequences; black arrows, antibiotic resistance markers; white arrows, lacP sequences; white 
batched arrows, tpa sequences; and white hatched bars, Es sequences. 
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The next step in the purification process was optimizing the cell lysing conditions and the 
effect of denaturation conditions on yield. Three different techniques were used for cell lysing, 
French press, sonication and freeze-thawing. The French press gave little purified product and 
was abandoned after the initial trails (data not shown). Sonication usually resulted in degraded 
products for unknown reasons. Freeze-thaw (3-5 cycles) with lysozyme treatment gave the best 
results. Protease inhibitors were added during cell lysis to prevent protease degradation. The 
effect of 8 M urea on purification was also tested. For P97, and P71 proteins, urea was not 
necessary, but it was essential to the purification of Es protein. For both Es fusion proteins, Es-
F97 and Es-P71, urea was added during cell lysis. 
The third step in the purification process was determining the best chromatography resin for 
optimizing purification yields. Several resins were tested, ProBond resin (Invitrogen), Fast Flow 
Chelating Sepharose used with FPLC (Pharmacia), and Talon Metal Affinity Resin (Clontech). 
Each purification experiment used conditions recommended by the manufacturer with minor 
modifications. When urea was used to lyse the cells and denature the protein, it was included m 
the column-binding buffer, washing buffers and elution buffer for Es protein. For Es-P97 and 
ES-P71 proteins, urea was not added after the first wash or in the elution buffer. Table 5 
summarizes the optimal conditions for purification of each protein. 
The yield of purified proteins varied between batches. The yields were approximately 2 mg 
of Es, 5.4 mg of P97,6.5 mg of Es-P97,5.6 mg of P71 and 8 mg of Es-P71 per liter of induced 
culture. The yields in the case of Es, P97 and Es-P97 represent the average of at least three 
different purification trials while that for P71 and Es-P71 were that firam a single experiment. 
The cells present in one liter were concentrated by pelleting and resuspending in 60 ml of lysis 
buffer representing a 12-fold concentration. The protein was then bound to the resin and eluted 
in 10 mis of buffer, representing a 6-fold concentration. The eluent was then dialyzed and 
concentrated another 10-fold by resuspending the protein into 1 ml of sterile water. Total 
purification represented l(X)0-fold. 
Protein Immunization Studies 
Mice were immunized with purified proteins according to the schedule in the Materials and 
Methods. For P97 studies, IFA was included in the immunizations, but for the P71 studies, IFA 
was not included. 
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Table 5. Optimal conditions for protein purification* 
Es P71 P97 EsP71 EsP97 
CeU Cirowm 
LB + + + + + 
2XYT + + ND + + ND ND 
SB + + + + + + + + + + 
Cell lysis 
French Press ND ND + ND + 
sonication + ND + ND + 
feeze-thaw + + + + + + + + + + 
8 M urea R + +/- + + 
Resin 
ProBond + ND + ND + 
Chelating Sepharose ND ND + ND + 
Talon + + + + + + + -I- + + 
* Score = +, some product, poor yield or contaminating proteins for resin designations; ++, 
best conditions; +/-, either condition would work satisfactorily; R, required; ND, not done. 
Blastogenesis 
The proliferative responses of splenocytes, an indicator of overall antigen-specific cell 
responsiveness, were measured by pooling the cells from 3 mice per group and determining the 
incorporation of [^H] thymidine following stimulation with specific antigen at 1 and 10 pg per 
ml antigen concentrations. For each group, three antigens were used for stimulation; Es, Es-
P97(P71), or P97(P71). Controls consisted of no antigen and Concanavalin A. All 
measurements were made in triplicate and the average was determined. The stimulation index 
(SI) was calculated using the following formula: 
SI = average cpm of experimental/average cpm nonstimulated control 
The mice vaccinated with recombinant P97 and fused EsP97 proteins when stimulated with 10 
Hg per ml of the P97 antigen, gave low blastogenic stimulation on day 25 (Fig. 7). On day 35, 
the P97 and EsP97 vaccinates showed a stimulation index (SI) of 25 and 54, respectively. 
When stimulated with 1 pg per ml of P97 antigen, the P97 and EsP97 vaccinates showed 
stimulation indices of 7 and 10 on day 25 and 83 and 60 on day 35, respectively. 
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Figure. 7. Stimulation indices of P97 protein vaccinates. Data represent the mean plus standard 
error for two experiments. Black bars, 1 ng stimulation on day 25; white bars, 1 pg on day 35; 
gray bars, 10 |ig on day 25; hatched bars, 10 |jg on day 35. 
Table 6 gives the individual experiment results of each group stimulated with the three proteins, 
Es, P97 and EsP97, and the Concanavalin A and negative controls. Table 7 gives the individual 
experiment results of each group stimulated with the three proteins, Es, P71 and EsP71, and the 
Concanavalin A and negative controls. The mice vaccinated with the recombinant P71 and 
EsP71 proteins when stimulated with 10 pg per ml of P71 antigen, gave a stimulation index of 
20 and 13, respectively, compared to 25 for the control cells on day 25 (Fig. 8). On day 35, the 
stimulation indices were 7,30 and 26 for the control, P71 and EsP71, respectively. With 1 |ig 
per ml of antigenic stimulation, the SI on day 25 were 5,17 and 70 while on day 35 the SI were 
5,30 and 21 for the control, P71 and EsP71, respectively. The P71 seems to be a mitogenic 
protein at 10 \ig per ml levels. 
Table 6. Blastogenesis results of P97 protein vaccinates'^ 
CPMs SI 
Day group NS Es P97 EsP97 NS^ ConA Es P97 EsP97 ConA 
Exp. 1 
1 Mg 25 C 4097 96530 23.6 
Es 3069 130624 42.6 
P97 4552 90778 19.9 
EsP97 4543 134794 29.7 
1 MB 35 C 350 701 1286 657 881 21494 2.0 3.7 31.9 24.4 
Es 280 4995 11921 7824 634 33259 17.8 42.6 27.9 52.5 
P97 461 9746 46498 34930 585 64597 21.1 94.4 75.8 110.4 
EsP97 670 7498 42494 57832 739 190830 11.2 63.4 86.3 258.2 
10 Mg 25 C 4111 6273 42541 33140 1.5 10.3 8.1 
Es 5674 25565 38036 41748 4.5 6.7 7.4 
P97 5000 21465 3778 14672 4.3 0.8 2.9 
EsP97 11101 18623 11767 12673 1.7 1.1 1.1 
35 C 882 1064 1357 1154 1.2 1.5 1.3 
Es 624 7973 12304 16163 12.8 19.7 25.9 
P97 528 7292 8595 17886 13.8 16.3 33.9 
EsP97 536 14426 39646 43083 26.9 74.0 80.4 
Exp. 2 
1 Mg 25 C 12462 19717 29481 11648 8312 153939 1.6 2.4 0.9 18.5 
Es 24410 114453 154921 87924 8564 199229 4.7 6.3 3.6 23.3 
P97 22593 128588 168042 141836 10279 113040 5.7 7.4 6.3 11 
EsP97 16246 141080 163358 124656 10104 154241 8.7 10.1 7.7 15.3 
35 C 3783 10681 28907 8252 2766 112724 2.8 7.6 2.2 40.8 
Es 3586 57593 121278 53157 2346 131864 16.1 3.8 14.8 56.2 
P97 2794 86926 200436 79007 2688 163934 31.1 71.7 28.3 61 
EsP97 1963 71859 111336 68383 1285 172850 36.6 56.7 34.8 134.5 
25 C 12091 6857 7797 5713 0.6 0.6 0.5 
Es 11257 18791 9596 28866 1.7 0.9 2.6 
P97 16334 30006 18712 21695 1.8 1.1 1.3 
EsP97 27624 36964 29052 24720 1.3 1.1 0.9 
35 C 1505 2870 21580 7011 1.9 14.3 4.7 
Es 1136 33102 35059 35106 29.1 30.9 30.9 
P97 2614 71827 87861 68258 27.5 33.6 26.1 
EsP97 2552 69128 84556 51433 27.1 33.1 20.2 
•The data represent average values in counts per minute (cpm) from three wells when pooled splenocytes (three mice/group/time 
point) were stimulated with either 1 or 10 ^g per ml of one of the recombinant purified Es, P97 or EsP97 proteins. The quantity of 
stimulating antigen (1 and 10 fig) and the day of the vaccination regimen (day 25 or day 35) is indicated. Group indicates the 
vaccinate group; C, control. The stimulating antigen is indicated by column. Negative controls (NS, NS^) contained only media. 
Positive controls (ConA) were stimulated with Ifig per ml of Con A. The stimulation indices (SI) were calculated by dividing the 
average cpms of the stimulated cells by the average cpm of non-stimulated cells. 
Table 7. Blastogenesis results of P71 protein vaccinates'" 
CPMs SI 
Day group NS Es P71 EsP71 NS ConA Es P71 EsP71 ConA 
p. 5 
1 Mg 25 C 5671 2728 18847 25375 2821 103310 0.5 3.3 4.5 36.6 
Es 2154 6513 15500 23487 1071 79279 3.0 7.2 10.9 74 
P71 1003 2301 18697 13479 2912 95369 2.3 18.6 13.4 32.8 
EsP71 849 5942 48162 29578 1887 132067 7.0 56.7 34.8 70 
35 C 3925 4392 15241 7734 841 52849 1.1 3.9 2.0 62.8 
Es 1997 11546 23649 14098 1232 91841 5.8 11.8 7.1 74.5 
P71 3084 20253 71388 51530 1892 113516 6.6 23.1 16.7 60 
EsP71 2858 6367 53543 27698 1562 136451 2.2 18.7 9.7 87.4 
10 ng 25 C 2777 1756 70262 12499 0.6 25.3 4.5 
Es 3639 9394 73636 37751 2.6 20.2 10.4 
P71 2837 4957 54444 37456 1.7 19.2 13.2 
EsP71 3287 8567 32075 70471 2.6 9.8 21.4 
35 C 2465 4532 17100 9524 1.8 6.9 3.9 
Es 1918 20270 58741 29504 10.6 30.6 15.4 
P71 2794 30256 102545 80138 10.8 36.7 28.7 
EsP71 2010 15651 52656 40916 7.8 26.2 20.4 
ip. 6 
1 Mg 25 C 1944 2638 14237 10243 2817 137568 1.4 7.3 5.3 48.8 
Es 5429 8575 30197 13348 2475 103354 1.6 5.6 2.5 41.8 
P71 2539 6547 36447 23706 3485 113616 2.6 14.4 9.3 32.6 
EsP71 514 3573 42808 22693 2094 146927 7.0 83.3 44.1 70.2 
35 C 2305 2893 13220 7479 1469 102130 1.3 5.7 3.2 69.5 
Es 1507 11461 21620 13586 1970 154596 7.6 14.3 9.0 78.5 
P71 2143 31692 79451 71488 1707 122172 14.8 37.1 33.4 71.6 
EsP71 2085 14401 48134 34906 2168 142334 6.9 23.1 16.7 65.7 
25 C 1748 2019 42010 20862 1.2 24.0 11.9 
Es 3216 13385 62546 39281 4.2 19.4 12.2 
P71 3930 12042 79136 79771 3.1 20.1 20.3 
EsP71 4320 14573 67556 81544 3.4 15.6 18.9 
35 C 2618 7321 19811 9177 2.8 7.6 3.5 
Es 2459 22808 52332 25677 9.3 21.3 10.4 
P71 4851 38793 111034 91708 8.0 22.9 18.9 
EsP71 2409 21468 61990 46404 8.9 25.7 19.3 
^The data represent average values in counts per minute (cpm) from three wells when pooled splenocytes (three mice/group/time 
point) were stimulated with either 1 or 10 ^g per ml of one of the recombinant purified Es, P71 or EsP71 proteins. The quantity of 
stimulating antigen (1 and 10 pg) and the day of the vaccination regimen (day 25 or day 35) is indicated. Group indicates the 
vaccinate group; C, control. The stimulating antigen is indicated by column. Negative controls (NS, NS^) contained only media. 
Positive controls (ConA) were stimulated with l^g per ml of ConA. The stimulation indices (SI) were calculated by dividing the 
average cpms of the stimulated cells by the average cpm of non-stimulated cells. 
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Figure 8. Stimulation indices of P71 protein vaccinates. Data represent the mean plus standard 
error for two experiments. Black bars, 1 ng stimulation on day 25; white bars, 1 ng on day 35; 
gray bars, 10 |jg on day 25; hatched bars, 10 pg on day 35. 
Induction of IL>10 
To estimate antigen-specific 11-10 release, a down regulator of Type I immune responses, a 
standard curve was generated using serial dilutions of recombinant mouse IL-10. When 
stimulated with P97 protein on day 25, the splenocytes from mice vaccinated with recombinant 
P97 secreted IL-10 at approximately 2.5 times the level of the recombinant EsP97 vaccinates 
(Fig. 9). The control cells secreted 2.8 ng per ml in response to P97 antigenic stimulation. On 
day 35, IL-10 could only be detected in the culture supernatant of 1*97 at the level of 1. Ing per 
ml. When stimulated with P71 protein on day 25, the splenocytes from mice vaccinated with 
recombinant P71 secreted more than 3 times the amount of IL-10 secreted by EsP71 (Fig. 10). 
The control cells secreted 0.6 ng per ml of 11-10 as well on day 25. On day 35,11-10 could be 
detected only with the splenocytes from P71 vaccinates. The estimated IL-10 concentration was 
approximately similar to what was estimated of the culture supernatant on day 25. 
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Figure 9. IL-10 levels in P91 protein vaccinates. Data represents mean plus standard error for 
two experiments. White bars, day 25; gray bar, day 35. 
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Figure 10. IL-10 levels in P71 protein vaccinates. Data represents mean plus standard error for 
two experiments. White bars, day 25; gray bar, day 35. 
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Induction of IFN-y 
The pooled splenocytes from mice vaccinated with recombinant EsP97 protein in IFA when 
stimulated with P97 protein secreted approximately 3 times more IFN-y on day 25 as compared 
to P97 vaccinates alone (Fig. 11). On day 35, stimulated splenocytes from the P97 vaccinates 
secreted twice the amount of IFN-y compared to the EsP97 vaccinates even though the secreted 
levels of IFN-y were much lower compared to day 25 (Fig. 11). Mice vaccinated with 
recombinant EsP71 protein gave antigen specific IFN-y estimates of 10 lU per ml of the culture 
supernatant while the P71 vaccinates failed to secrete detectable levels of IFN-y on day 25 (Fig. 
12). On day 35, EFN-y could be measured in the culture supernatant for both groups. The IFN-
y levels showed an upward trend on day 35. 
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Figure 11. IFN-y levels of P97 protein vaccinates. Data represent mean plus standard error 
of two experiments. White bars, day 25; gray bars, day 35. 
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Figure 12. IFN-y levels of P71 protein vaccinates. Data represent mean plus standard error of 
two experiments. White bar, day 25; gray bars, day 35. An asterisk indicates that the value was 
significantly different from the other vaccinate group for the same time point. 
IgGl and IgG2a responses 
Both classes of IgG were measured in the same plate for each experiment. The cut off value 
was taken as the average of the OD 405 readings for the control mice sera plus twice the 
standard deviation. Figure 13 shows the IgGl and IgG2a levels for the P97 protein vaccinates. 
During the course of the first P97 protein vaccination experiment, one mouse belonging to the 
EsP97 group died for unknown reasons prior to sacrifice. Therefore, the value on the graph for 
EsP97 vaccinate group represents the average value for 5 mice + SEM on day 25. Both the P97 
and EsP97 vaccinate groups had higher mean IgGl levels as well as IgG2a levels on day 35 
compared to day 25. There was no difference in IgG2a values between vaccinate groups on 
days 25 and 35. The mean IgGl values, however, were lower on both days for the EsP97 
vaccinates. In the P71 and EsP71 vaccinates, all mice seroconverted for both IgGl and IgG2a. 
The IgGl levels were approximately the same for both P71 and EsP71 vaccinates on both days 
(Fig. 14). The IgGl levels showed an increase firom day 25 to day 35 for both vaccinate groups 
while the IgG2a level for P71 vaccinates decreased firam day 25 to day 35. The IgG2a levels for 
the EsP71 vaccinates were significantly higher on both days compared to that for F71 
vaccinates (Fig. 14). For P71 vaccinates, the levels of IgGl to IgG2a were the same on day 25, 
but the IgGl levels showed an increase by day 35. For EsP71 vaccinates, IgGl levels also 
increased by day 35 even though IgG2a levels were slightly higher than IgGl levels on day 25. 
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Figure 13. IgGl and IgG2a antibody levels in P97 protein vaccinates. Data represents the mean 
plus standard error for two experiments. White bars, day 25; gray bars, day 35. 
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Figure 14. IgGl and IgG2a antibody levels in P71 protein vaccinates. Data represents the mean 
plus standard error for two experiments. White bars, day 25; gray bars, day 35. An asterisk 
indicates that the value was significantly different fix)m the other vaccinate group for the same 
time point. 
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Genetic Immunization Studies 
Biastogenesis 
Splenocytes obtained from DNA immunized mice with the P97 and EsP97 pVR1012-
derived plasmid constructs were stimulated with P97 protein at I and 10 pg per ml 
concentration and the blastogenic responses measured. At 1 pg per ml there was slight increase 
of the stimulation index on days 32 and 42 (Fig, 15). At 10 |ig per ml, however, there was a 
significant increase in the stimulation index over control values in both the P97 and EsP97 
vaccinated animals on day 32. The stimulation index on day 32 was significantly higher than on 
day 42, which returned to control levels. The values in the EsP97 vaccinates also were higher in 
the cells stimulated with 10 pg of P97 per ml. The biastogenesis values are presented in Table 
8. 
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Figure 15. Biastogenesis results for P97 genetic vaccinates. Data represent the mean plus 
standard error for two experiments. Black bars, 1 ^g stimulation on day 32; white bars, 1 pg on 
day 42; gray bars, 10 ^g on day 32; hatched bars, 10 Mg on day 42. 
Table 8. Blastogenesis results of P97 genetic vaccinates (VR1012). 
Exp. 3 
1 Mg 
10 pg 
Exp. 4 
1 Mg 
CPMs SI 
Day group NS Es P97 EsP97 NS ConA Es P97 EsP97 ConA 
32 C 1623 10768 28796 18802 1931 130786 6.6 17.7 11.6 67.7 
Es 1573 14579 28815 25403 2533 159661 9.3 18.3 16.1 63 
P97 1026 8538 33554 13649 1331 57667 8.3 32.7 13.3 43.3 
EsP97 891 6634 30106 26410 1874 132490 7.4 33.8 29.6 70.7 
42 C 4886 15140 40961 36673 3250 42748 3.1 8.4 7.5 13.2 
Es 4276 20534 46683 31524 2803 43954 4.8 10.9 7.4 15.7 
P97 6391 31220 87071 80422 4535 60824 4.9 13.6 12.6 13.4 
EsP97 4118 15427 43735 35722 2008 74818 3.7 10.6 8.7 37.3 
32 C 1498 8312 16879 18569 5.5 11.3 12.4 
Es 1526 16801 37309 48040 11.0 24.4 31.5 
P97 2015 21330 50927 48476 10.6 25.3 24.1 
EsP97 1560 29074 53728 51135 18.6 34.4 32.8 
42 C 1970 6981 13091 35780 3.5 6.6 18.2 
Es 4054 34445 23811 48212 8.5 5.9 11.9 
P97 5176 31711 58672 37246 6.1 11.3 7.2 
EsP97 13115 30242 12069 25212 2.3 0.9 1.9 
32 C 2222 6076 19063 12535 3005 85384 2.7 8.6 5.6 28.4 
Es 2173 15654 47141 24572 1982 141900 7.2 21.7 11.3 71.6 
P97 2731 16204 25072 16435 4589 140011 5.9 9.2 6.0 30.5 
EsP97 3883 9672 40026 29044 2956 136659 2.5 10.3 7.5 46.2 
42 C 5357 33399 40186 16029 4221 76419 6.2 7.5 3.0 18.1 
Es 6082 44957 46830 24025 1616 147182 7.4 7.7 4.0 91.1 
P97 4234 31048 46269 17181 1765 101951 7.3 10.9 4.1 57.8 
EsP97 1766 9432 23352 5531 1690 111497 5.3 13.2 3.1 66 
32 C 1394 10626 27863 16999 7.6 20.0 12.2 
Es 2749 21023 60878 30847 7.6 22.1 11.2 
P97 1672 27722 51227 32994 16.6 30.6 19.7 
EsP97 1633 37046 71461 38625 22.7 43.8 23.7 
42 C 1035 13292 33887 9621 12.8 32.7 9.3 
Es 2261 29137 67731 29173 12.9 30.0 12.9 
P97 3710 35836 57999 20233 9.7 15.6 5.5 
EsP97 1932 24042 36102 19689 12.4 18.7 10.2 
"'The data represent average values in counts per minute (cpm) from three wells when pooled splenocytes (three mice/group/time 
point) were stimulated with either 1 or 10 ^g per ml of one of the recombinant purified Es, P97 or EsP97 proteins. The quantity of 
stimulating antigen (1 and 10 ^g) and the day of the vaccination regimen (day 32 or day 42) is indicated. Group indicates the 
vaccinate group; C, control. The stimulating antigen is indicated by column. Negative controls (NS, NS^) contained only media. 
Positive controls (ConA) were stimulated with l^g per ml of Con A. The stimulation indices (SI) were calculated by dividing the 
average cpms of the stimulated cells by the average cpm of non-stimulated cells. 
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Splenocytes obtained from genetic immunized mice with the P71 and EsP71 pVR1012-
derived plasmid constructs were stimulated with 1 and 10 |ig per ml and the blastogenic 
responses measured. When stimulated with either lor 10 ^g per ml of P71 antigen, the 
blastogenic responses showed Uttle difference on days 32 and 42 (Fig. 16). On day 42 when 
stimulated with 10 pg per ml antigen, however, the values were higher in the P71 immunized 
animals than in the EsP71 immunized animals. 
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Figure 16. Stimulation indices of F71 pVR1012 vaccinates. Data represent the mean plus 
standard error for two experiments. Black bars, 1 pg stimulation on day 32; white bars, 1 pg on 
day 42; gray bars, 10 pg on day 32; hatched bars, 10 ^ig on day 42. 
When stimulated with 10 pg of P71 antigen per ml, splenocytes obtained from mice 
immunized with the pVR1020-derived P71-coQtaining plasmids gave a SI of 8,15 and 9 on day 
32 and a SI of 16,18, and 6 on day 42 for the control, P71 and EsP7I groups, respectively (Fig. 
17). At a concentration of 1 \ig per ml, the SI was 6,13 and 6 on day 32 and 6,7 and 7 on day 
42 for the control, P71 and EsP71 groups, respectively. The blastogenesis values of these 
experiments are presented in Tables 9 and 10. 
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Figure 17. Stimulation indices of P71 pVRI020 vaccinates. Data represent the mean plus 
standard error for two experiments. Black bars, I pg stimulation on day 32; white bars, 1 |jg on 
day 42; gray bars, 10 jig on day 32; hatched bars, 10 |ig on day 42. 
Induction of IL-10 
Figures 18 and 19 show the IL-10 results of stimulating splenocytes from mice immunized 
with the genetic plasmid constmcts. When stimulated with purified P97 antigen on day 32, 
splenocytes from mice immunized with the pVR1012 P97 constracts released 0.8 ng per ml IL-
10 for ?91 vaccinates while it could not be detected for EsP97 vaccinates (Fig. 18). In these 
experiments, the control cells secreted detectable levels of IL-10 only on day 32. On day 35, the 
n-lO levels were 10 times higher in the culture supernatant for the P97 compared to EsP97 
vaccinates. When stimulated with P71 purified antigen, the splenocytes from mice immunized 
with the P71 pVR1012 plasmid constructs did not secrete any detectable levels of IL-10 on day 
32 (Fig. 19). However, on day 42, IL-10 was detected in the culture supernatant for both the 
P71 and EsF71 vaccinates. The IL-10 level for the P71 vaccinates was 10 times higher than the 
level for EsP97 vaccinates. Interestingly, the splenocytes from the pVR1020 P71 immunized 
mice when stimulated with recombinant P71 secreted detectable levels of IL-10 only with the 
P71 vaccinates. The IL-10 levels were 0.8 and 0.9 ng/on day 32 and day 42, respectively (Fig. 
19). 
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Figure 18. IL-10 levels in splenocytes derived from mice immunized with pVR1012 P97 
plasmid consUructs when stimulated with P97 protein. Data represents die mean plus standard 
error for two experiments. White bars, day 32; gray bars, day 42. 
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Figure 19. IL-10 levels in splenocytes derived from mice immunized with pVR1012 or 
pVR1020 P71 plasmid constructs when stimulated with P71 antigen. Data represents the mean 
plus standard error for two experiments. White bar, day 32; gray bars, day 42. An asterisk 
indicates that the value was significantly different from the other vaccinate group for the same 
time point. 
Table 9. Blastogenesis results of P71 genetic vaccinates (VR1012). 
Exp. 7 
1 Mg 
10 ng 
Exp. 8 
1 Mg 
CPMs SI 
Day group NS Es P97 EsP97 NS ConA Es P97 EsP97 ConA 
32 C 4135 4645 16034 10763 1921 86842 1.1 3.9 2.6 45.2 
Es 6626 8169 32941 28346 2050 215830 1.2 5.0 4.3 105.3 
P71 4880 11017 51829 27807 7390 156099 2.3 10.6 5.7 21.1 
EsP71 2206 3619 17325 22040 2798 160050 1.6 7.9 10.0 57.2 
42 C 2018 3807 19692 10803 2445 44984 1.9 9.8 5.4 18.4 
Es 7966 10859 25213 21269 3021 69221 1.4 3.2 2.7 22.9 
P71 9230 21002 79350 32228 3683 90167 2.3 8.6 3.5 24.5 
EsP71 4061 10614 58538 77193 3504 78609 2.6 14.4 19.0 22.4 
32 C 1671 3634 19619 6175 2.2 11.7 3.7 
Es 7289 8275 26446 15744 1.1 3.6 2.2 
P71 4497 17638 47734 26717 3.9 10.6 5.9 
EsP71 2226 9925 16951 14673 4.5 7.6 6.6 
42 C 2171 7175 20045 4407 3.3 9.2 2.0 
Es 4072 20232 34924 22310 5.0 8.6 5.5 
P71 3977 21606 47870 36971 5.4 12.0 9.3 
EsP71 8457 17287 53131 58957 2.0 6.3 7.0 
32 C 3268 6597 20413 12552 1610 57419 2.0 6.2 3.8 35.7 
Es 2128 2610 8935 10060 1533 185633 1.2 4.2 4.7 121.1 
P71 8767 7821 38860 25581 3363 170026 0.9 4.4 2.9 50.6 
EsP71 2318 4020 32649 17648 2556 161829 1.7 14.1 7.6 63.3 
42 C 1944 1127 12529 4147 1674 7248 0.6 6.4 2.1 4.3 
Es 3856 9362 21099 7572 1714 29680 2.4 5.5 2.0 17.3 
P71 4004 821 67702 12439 3894 15346 0.2 16.9 3.1 3.9 
EsP71 4118 453 32532 3354 2560 21247 0.1 7.9 0.8 8.3 
32 C 2129 4469 15059 8829 2.1 7.1 4.1 
Es 2202 2891 6538 5268 1.3 3.0 2.4 
P71 4762 10390 40533 24795 2.2 8.5 5.2 
EsP71 4078 7159 50991 20937 1.8 12.5 5.1 
42 C 1087 1617 10275 6005 1.5 9.5 5.5 
Es 1488 6667 33562 18089 4.5 22.6 12.2 
P71 2371 5911 57946 28199 2.5 24.4 11.9 
EsP71 3426 4696 46476 38244 1.4 13.6 11.2 
*The data represent average values in counts per minute (cpm) from three wells when pooled splenocytes (three mice/group/time 
point) were stimulated with either 1 or 10 ^g per ml of one of the recombinant purified Es, P71 or EsP71 proteins. The quantity of 
stimulating antigen (1 and 10 ^g) and the day of the vaccination regimen (day 32 or day 42) is indicated. Group indicates the 
vaccinate group; C, control. The stimulating antigen is indicated by colunui. Negative controls (NS, NS^) contained only media. 
Positive controls (Con A) were stimulated with l|xg per ml of Con A. The stimulation indices (SI) were calculated by dividing the 
average cpms of the stimulated cells by the average cpm of non-stimulated cells. 
Table 10. Blastogenesis results of P71 genetic vaccinates (VR1020). 
Day group 
CPMs SI 
NS Es P97 EsP97 NS ConA Es P97 EsP97 ConA 
Exp. 9 
1 Mg 32 C 2308 4592 17078 11953 2232 165289 2.0 7.4 5.2 74.1 
Es 12519 10807 39003 25499 7418 220921 0.9 3.1 2.0 29.8 
P71 6331 5055 31025 22859 3628 172313 0.8 4.9 3.6 47.5 
EsP71 22187 40720 130414 125579 7744 157677 1.8 5.9 5.7 20.3 
42 C 1631 1752 8111 3011 2102 58003 1.1 5.0 1.8 27.6 
Es 4353 9227 29271 20972 3345 158890 2.1 6.7 4.8 47.5 
P71 9449 22497 74210 68646 3651 137152 2.4 7.9 7.3 37.6 
EsP71 14323 38022 82717 73251 6483 128999 2.7 5.8 5.1 19.9 
10 Hg 32 C 2778 5162 21671 13417 1.9 7.8 4.8 
Es 10785 16892 41722 34173 1.6 3.9 3.2 
P71 4112 12071 40217 19336 2.9 9.8 4.7 
EsP71 12409 50349 137807 110267 4.1 11.1 8.9 
42 C 1284 3267 20797 4783 2.5 16.2 3.7 
Es 2489 14734 37655 20789 5.9 15.1 8.4 
P71 5602 28011 59134 67175 5.0 10.6 12.0 
EsP71 12684 33916 82596 91246 2.7 6.5 7.2 
Exp. 10 
1 Mg 32 C 1064 1053 5219 3454 1690 219923 1.0 4.9 3.2 130 
Es 3039 3834 24263 16279 3404 252234 1.3 8.0 5.4 74.1 
P71 2075 3370 41740 20642 3416 214824 1.6 20.1 9.9 62.9 
EsP71 12626 10219 68525 52842 5456 253554 0.8 5.4 4.2 46.5 
42 C 1957 2883 11947 4212 2748 22698 1.5 6.1 2.2 8.3 
Es 5708 20331 26440 25885 4290 33792 3.6 4.6 4.5 7.9 
P71 9345 9578 55587 41973 3953 48416 1.0 5.9 4.5 12.2 
EsP71 13950 37211 120993 131003 7980 61442 2.7 8.7 9.4 7.7 
32 C 674 927 5846 1953 1.4 8.7 2.9 
Es 3020 5049 32631 13987 1.7 10.8 4.6 
P71 2136 7121 43146 19579 3.3 20.2 9.2 
EsP71 11015 16474 71707 74601 1.5 6.5 6.8 
42 C 1923 8368 31073 15259 4.4 16.2 7.9 
Es 3857 27693 48429 43143 7.2 12.6 11.2 
P71 2297 13979 59102 38167 6.1 25.7 16.6 
EsP71 12699 36759 79277 142576 2.9 6.2 11.2 
*The data represent average values in counts per minute (cpm) from three wells when pooled splenocytes (three mice/group/time 
point) were stimulated with either 1 or 10 ^g per ml of one of the recombinant purified Es, P71 or EsP71 proteins. The quantity of 
stimulating antigen (1 and 10 ^g) and the day of the vaccination regimen (day 32 or day 42) is indicated. Group indicates the 
vaccinate group; C, control. The stimulating antigen is indicated by column. Negative controls (NS, NS^) contained only media. 
Positive controls (Con A) were stimulated with l^g per ml of Con A. The stimulation indices (SI) were calculated by dividing the 
average cpms of the stimulated cells by the average cpm of non-stimulated cells. 
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Induction of IFN-y 
Splenocytes from mice immunized with the P97 pVR1012 plasmid constructs were 
stimulated with P97 antigen, and the IFN-y levels in the culture supernatant was measured. 
Figure 20 shows the results of those studies. IFN-y was not detected in control cells, but P97 
pVR1012 vaccinates demonstrated IFN-y induction on days 32 and 42. The levels of IFN-y on 
day 42 were higher than on day 32. The IFN-y levels of the EsP97 pVR1012 vaccinates were 
lower than the P97 pVR1012 vaccinates. The levels were similar on both days in those cells. 
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Figure 20. INF-y levels in splenocytes obtained from P97 pVR1012 vaccinates. Data represents 
the mean plus standard error for two experiments. White bars, day 32; gray bars, day 42. 
Splenocytes from mice immunized with the P71 pVR1012 plasmid constructs secreted 
significant levels of IFN-y on day 32 when stimulated with purified P71 protein (Fig. 21). The 
levels quickly decreased by day 42. There appeared to be no difference between P71 vaccinate 
groups for either day. The P71 pVR1020 vaccinates showed a significant difference between 
groups, however. The EsP71 pVR1020 vaccinates had higher levels of IFN-y on days 32 and 
42 when compared to the pVR1012 plasmid constructs (Fig. 21). The difference between the 
P71 and EsP71 vaccinates in the pVR1020 constructs was about 10-foId on day 32. Day 32 
IFN-y levels were higher than on day 42. 
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Figure 21. INF-y levels in splenocytes obtained from P71 pVR1012 and pVR1020 vaccinates. 
Data represents the mean plus standard error for two experiments. White bars, day 32; gray 
bars, day 42. 
IgGl and IgG2a responses 
The IgGl and IgG2a serum antibody responses were measured on the day of necropsy in 
mice immunized with pVR1012 DNA constructs for P97. The results of those studies are 
shown in Figure 22. IgGl levels were measurable only on day 32 in both the P97 and the 
EsP97 vaccinates. IgG2a levels decreased slightly on day 42 as compared to day 32 in the 
pVR1012 P97 vaccinates. The opposite was true for the EsP97 pVR1012 vaccinates. 
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Figure 22. IgGl and IgG2a serum antibody levels in mice immunized with P97 pVR1012 
constructs. Data represents the mean plus standard error for two experiments. White bars, day 
32; gray bars, day 42. 
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Figure 23 shows the results of the serum antibody isotype levels in mice immunized with 
the P7I pVR1012 and pVR1020 constructs. In the genetic immunized mice with pVR1012 
DNA constructs, only 2 out of 6 of the P71 vaccinates seroconverted for IgGl per time point 
(data not shown). In the case of EsP71 vaccinates, 3 seroconverted by day 32 and 5 out of the 6 
seroconverted for IgGl by day 42 (data not shown). The level of IgGl in the pVR1012 
vaccinates remained the same for both time points in both groups. For IgG2a, only one of the 
P71 vaccinates seroconverted by day 32 and two by day 42 while all the EsP71 vaccinates 
seroconverted by both days. The levels of IgG2a antibodies were not significantly different for 
the two vaccinate groups with the pVR1012 vaccmates (Fig. 23). For F71 vaccinates, the IgGl 
to IgG2a ratio remained almost the same between day 32 and day 42. For EsP71, the levels of 
IgGl were higher on day 32 compared to IgG2a, and the levels of IgG2a increased by day 42 
(Fig. 23). 
In the genetic immunized mice with pVR1020 DNA constructs for P71 and EsP71,4 out of 
the six mice seroconverted on day 32 in the P71 vaccinates and all six mice seroconverted on 
day 42 while all the mice at both the time points seroconverted for EsP71 for IgGl, The levels 
of IgG 1 showed an increase for both F71 as well as EsP71 vaccinates from day 32 to day 42. 
The EsP71 vaccinates showed somewhat higher levels of IgGl at both time points compared to 
F71 that were not significant. For the IgG2a isotype, two of the P71 vaccinates seroconverted 
on day 32 while 5 out of the 6 seroconverted on day 42. All EsP71 vaccinates seroconverted for 
both days 32 and 42.The IgG2a levels were significantly higher on both days 32 and 42 for 
EsP71 vaccinates compared to P71 vaccinates (Fig. 23). While the levels of both IgG2a and 
IgGl remained the same for day 42 with p71 vaccinates, IgGl levels increased with EsP71 
vaccinates by day 42 (Fig. 23). 
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Figure 23. IgGl and IgG2a serum antibody levels in mice immunized with P71 pVR1012 and 
pVR10120 constructs. Data represents the mean plus standard error for two experiments. Only 
positive sera were included in the analysis. White bars, day 32; gray bars, day 42. An asterisk 
indicates that the value was significantly different from the other vaccinate group for the same 
time point 
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DISCUSSION 
General Discussion 
This is the first report showing that the Af. tuberculosis Es protein can act as a molecular 
Type I-enhancing adjuvant when used in recombinant protein and genetic vaccinations. The 
cytokines measured in this study, IL-10 and INF-y, were chosen because of their role in T cell 
differentiation and regulation. Figure 24 diagrammatically represents the T cell differentiation 
pathways. Antagonistic regulation of Thl and Th2 cells is illustrated in Figure 25. Es generated 
better Type I responses when tested with two different M. hyopneumoniae antigens in mice. 
Protein fusions of Es and P97 or P71 enhanced Type I responses in mice as compared to the 
non-fused protein when presented either as purified recombinant proteins or in genetic vaccine 
constructs. The enhanced antigen-specific Type I responses were observed as an mitial surge of 
IFN-y release (Figs. 11,12, 20, and 21) and suppression of IL-10 release (Figs. 9, 10, 18, and 
19), and higher levels of IgG2a serum antibodies (Figs. 13, 14,22, and 23). This was generally 
true for both protein and genetic vaccinates. Thus, the hypothesis that Es can enhance Type I 
responses in mice to secondary antigens has been proven vaild. 
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Figure 24. T cell differentiation pathways. Antigen-presenting cells (APQ process antigen and 
present it in the context of MHC class H. This leads to autocrine activation of antigen-specific 
precursor T helper cells (PTh) by the release of 11-2. This leads to clonal expansion of the cells 
and initial differentiation to ThO cells. Depending upon the concentrations of certain cytokines, 
IL-12 or IL-4, the ThO cells differentiate into either Thl or Th2 cells. In addition to IL-12, 
IFN-y is required for Thl development. A preponderance of Thl cells leads to Type I immune 
responses while that of Th2 cells leads to Type 11 immune responses. 
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Figure 25. Antagonistic regulation of ThlATiI cells. The product of Thl cells, IFN-y, down 
regulates Th2 (Type II) responses while the product of Th2 cells, IL-10, down regulates Thl 
(Type I) responses. 
This project involved a number of technical hurdles that required solutions for its 
completion. One of the hurdles that had to be overcome was the screening of a genomic 
mycoplasma library, which presented a unique problem due to the different codon usage 
pattems of this bacterial species. Other technical problems arose in the site-directed 
mutagenesis experiments through failure of PGR reactions and improper primer design, 
optimizing protein purification and in the immunization experiments with establishing the 
proper control reactions and reagent concentrations. 
Cloning 
M. hyopneumoniae hke all Mycoplasma species, uses the UGA codon to preferentially code 
for tryptophan. This codon is a universal stop codon in almost all other organisms. The 
presence of these codons in cloned gene sequences results in truncation of translation products 
in E. coli and a failure to express many antigenic epitope(s) of the cloned gene sequences. This 
problem was overcome by using the E. coli strain ISM612 that has two opal (UGA) 
suppressors (91). One suppressor was trpT, which coded for a tRNA with a modified 
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anticodoa that recognized the UGA codon and was charged with tryptophan. The second 
suppressor was a loss-of-function mutation in release factor 2, the prfB3 mutation (51). Release 
factors are proteins that recognize stop codons and initiate the dissolution of the 
ribosomermRNA complex preventing ribosomal stalling at stop codons and promoting the 
recycling of ribosomes and translation-associated proteins in the cell. Release factor 2 
recognizes the UGA codon, and the pifB3 mutation causes ribosomal stalling, increases the 
probability of TrpT recognition of UGA and insertion of tryptophan into the growing 
polypeptide chain, and enhances the overall opal suppression efficiency (91). P97 and P71 gene 
sequences containing clones were both identified by screening a M. hyopneumoniae genomic 
library using strain ISM612 (46). The P97 gene sequence used in these studies was supplied 
by Kendall King and was identical in sequence to the M. hyopneumoniae P97 gene sequence 
cloned by Hsu et al. (46); the P71 gene sequence was cloned during the course of these studies. 
Although the ISM612 strain is useful for screening genomic libraries and for other 
preliminary smdies, its use as a host for purifying recombinant mycoplasma proteins is limited. 
This is due to the poor growth of ISM612 following induction of the trpT allele, which likely 
affects important £, coli proteins whose genes end m TGA. Opal suppressors are normally 
relatively inefficient, so TGA-ending genes are still expressed sufficiently well for normal E. 
coli growth. The enhanced opal suppression in ISM612, however, causes readthrough of E. coli 
TGA-ending genes thereby affecting the growth, probably because of low concentrations of 
functional product from these genes. 
Both P97 and P71 gene sequences encode multiple UGA codons within their reading 
frames, so it was necessary to replace these codons prior to use in these studies. A modified 
P97 gene sequence with UGA codons mutated to UGG was used as template DNA to obtain 
P97 gene sequences used in the constmction of all P97-containing plasmids in this study. It 
was necessary to perform site-directed mutagenesis of the P71 gene sequence, however. This 
was accomplished by using an overlap extension PGR technique (39). The PGR primers were 
designed such that 1) they could be used with similar annealing conditions (so that they could 
be used in any combination), 2) they would not form primer dimers at their 3' ends when used 
in any required combination, and 3) the mutated nucleotide (A to G transition) was at least 7 
nucleotides upstream from the primer 3' end to prevent the proof-reading Pfii polymerase from 
removing the mutations. 
Overlap extension worked for fusing fragments A and B, B and G and for fusing fragment 
AB with BG to make a single ABC fragment as described in Figure 1. Overlap extension 
performed to fuse fragments G with D, however, produced two fragments, only one of which 
was the correct size. Repeated attempts to amplify this fragment after gel purification resulted in 
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the generation of a smaller fragment. Hence, that approach was abandoned. Attempts to perform 
overlap extension with the ABC and D fragments also failed. It was therefore decided to 
introduce a BamlQ. site into the P71 sequence at nucleotide 930 (after the 3"* TGA) to facilitate 
cloning of fragment D in-frame. This altered two of the amino acids originally present in the 
wildtype E*71 protein. 
The P97 gene sequence had three of the four UGA codons modified to UGG. The fourth 
uiunodified UGA codon was located near the 3' terminal end of the gene. Previous studies in 
the laboratories of Drs. Minion and Ross have shown that the major antigenic epitope of this 
protein is in the cilium-binding region of the protein (46,47,115). This region lies upstream of 
the fourth UGA codon. Thus, the presence of this unmodified UGA codon with the resulting 
truncation of the carboxy terminus of the recombinant protein produced should not affect the 
antigenicity of the recombinant gene product. Since mice readily generated antibodies to 
recombinant P97 that recognized wildtype P97 protein (data not shown), the antigenicity of the 
protein was preserved even though it lacked the carboxy terminus. 
To facilitate cloning of the P97 gene sequences, it was decided to incorporate a Bc/I site 
while designing the PGR primers. The primers that were initially constructed (Fmhpl and 
Rmhpl) had three additional nucleotides preceding the BcR recognition sequence. However, 
attempts to clone the PGR fragment after digesting with flc/I repeatedly failed. New primers 
(Fmhp3 and Rmhp3) were constructed with eight additional nucleotides before the flc/I 
recognition sequence, and this change allowed the successful cloning of the digested fragment 
The failure of the original PGR product to be cloned may have been due to the higher 
temperature needed for digestion; BcR. requires incubation at SO°C. The high incubation 
temperature would result in increased breathing of the DNA duplex near the fragment ends 
thereby possibly inhibiting restriction digestion. By increasing the number of nucleotides 
between the end of the fragment and the BcR. site, the DNA duplex would more likely be 
retained at the higher temperature and restriction efficiency enhanced in the PGR fragment. An 
alternative explanation would be that BcR may require additional sequences outside the 6 base 
pair recognition sequence to interact properly with the DNA molecule. 
Each of the PGR reactions required optimization of the component concentrations and 
cycling parameters. For instance, the PGR reaction conditions for the P97 gene required a 
magnesium concentration of 3 mM for amplification. If a lower annealing temperature was used 
(40°G), however, a PGR product was obtained with 1.5 or 2 mM magnesium. This was also true 
for the site-directed mutagenesis reactions. It was also observed that Taq polymerase produced 
more PGR product than Pfu polymerase under similar reaction conditions. The Qiagen Q buffer 
gave better yields for some PGR reactions with lower levels of magnesium (data not shown). 
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The cloned P71 gene sequence lacked the first 31 amino acids representing the putative 
membrane-spanning domain. These hydrophobic regions often hamper purification of the 
recombinant gene product because of aggregation or instability. Elimination of this region of 
the protein also permitted fusion of tissue plasminogen activator signal sequences with the P71 
gene sequence for the genetic vaccination studies. 
Protein Purification 
To enhance recombinant protein expression, it was necessary to optimize the growth and 
induction conditions for each strain. The product was estimated by immunoblot analysis 
following alteration of culture or induction conditions. It was important to add additional 
ampicillin to the culture (100 fig per ml) prior to the addition of IPTG. This was probably due 
to P-lactamase degradation of ampicillin during normal growth with a concomitant reduction of 
plasmid copy number and gene copy. Carbenicillin is less sensitive to ^-lactamase activity and 
could have been added at lower concentration instead. 
Each recombinant protein was lyophilized to concentrate the protein. This presented 
problems only with Es. The lyophilized Es protein was not as soluble in water as compared to 
P97 or P71 proteins. It was also observed that the proteins dissolved in water precipitated after 
repeated freezing and thawing. 
Protein Immunization Studies 
In general, the blastogenic responses from recombinant protein vaccinates were optimal 
when splenocytes were stimulated with 1 pg of antigen per ml. Stimulation with 10 ^g per ml 
gave lower stimulation indices than the 1 ng per ml dose. Interestingly, both P97 vaccinate 
groups showed higher blastogenic responses on day 35 compared to day 25 while the 
blastogenic responses with the EsP71 vaccinate group actually decreased from day 25 to day 
35. It is notable that IFA was used with the P97 smdy. The combined adjuvant effect of both Es 
and IFA may be suppressing the blastogenic response in this cell population more rapidly than 
would be normally expected. An alternative explanation presented in more detail below is that 
the sensitized cells might have migrated from the spleen more rapidly in the presence of the two 
adjuvants thus lowering their numbers and the accompanying blastogenic response. 
Immunization with the purified non-fiision proteins led to a Th2 immune response. High 
levels of IL-4 or IL-IO tend to favor a Th2 response characterized by isotype switching to the 
IgGl isotype in mice. IL-10 was measured in all experimental groups. The splenocytes from 
conventional P97 or P71 protein vaccinates stimulated with 10 ^g of antigen per ml secreted IL-
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10 at higher levels at both time points compared to the Es protein vaccinates. However, the Es 
protein vaccinates secreted detectable levels of IL-10 only on day 25 and at a much lower level 
compared to their respective non-Es protein vaccinates. Comparison between the P97 and the 
P71 studies revealed that the levels of IL-10 released by all the groups belonging to P97 protein 
vaccinates were approximately three-fold higher than in the P71 vaccinates. This was probably 
due to the use of IFA with the P97 protein vaccinates. The presence of Es fused to P97 or P71 
seems to reduce the secreted levels of IL-10 upon antigen stimulation. This may down-regulate 
the normal Th2 type of immune response generated by vaccinating with the non-Es proteins. 
The presence of Es in the immunizing dose shifted the immune response towards a Thl 
response. Secretion of IFN-y stimulates a Th 1 response characterized by isotype switching to 
the IgG2a antibody class in mice. The splenocytes from mice vaccinated with Es proteins in 
both P97 and P71 studies showed an initial burst of IFN-y release on day 25 compared to 
splenocytes from their respective non-Es protein vaccinate group. Interestingly, the mean IFN-y 
levels in the F97 protein vaccinates decreased dramatically by day 35. This could indicate that 
sensitized lymphocytes had migrated from the spleen to other lymphoid organs of the body. In 
the case of the P71 studies, however, the mean IFN-y levels rose from day 25 to day 35 with 
both Es as well as non-Es vaccinate groups. Interestingly, the levels of IFN-y were several fold-
higher with the F97 study as compared to the P71 study. This could have been due to inherent 
differences between the F97 and P71 proteins or, more likely, to the use of IFA in the P97 
study which might have accelerated splenocyte maturation and migration. This line of 
investigation was not pursued. 
The relative levels of IgGl and IgG2a antibodies can be indicative of a Type I or Type H 
response in mouse models. A Type I response is characterized by higher levels of IgG2a while 
a Type II response is characterized by higher levels of IgGl. In the P71 study, the EsP71 
protein vaccinates generated significantly higher levels of IgG2a antibodies compared to the 
non-Es P71 vaccinate group at both time points. The P97 protein vaccinates showed high levels 
of both IgGl and IgG2a antibodies in their serum, and the mean levels of antibodies were 
higher on day 35 than on day 25. The IgG2a levels were not significantly different between 
days in this group as well. This could be an effect of IFA. The mean levels of IgGl generated 
by the EsP97 vaccinate group, however, were lower compared to non-Es P97 vaccinate group at 
both time points suggesting an effect by Es. There were no appreciable differences in the IgGl 
levels between the two P97 vaccinate groups for the two time points tested. This suggests an 
enhanced antigen-specific Type I response in mice inmiunized with Es fusion proteins. 
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Genetic Immunization studies 
Since genetic immunization enhances Type I responses, it was of interest to determine if Es 
affected that response. These studies were performed in parallel with die protein immunization 
studies so that a direct comparison of protein and DNA immunization with each specific antigen 
could be done. There were significant differences in the effect of Es between the protein and 
DNA immunized mice. There were also differences in the effect of the plasmid backbone, 
pVR1012 and pVR1020 in the P71 study. 
In previous smdies, bupivacaine was used to enhance genetic immunization results. 
Bupivacaine priming prior to genetic immunization is believed to cause better uptake of the 
injected plasmids during the healing process of the necrotic myositis. Hence, the immunization 
had to be done in the same muscle as close as possible to the site of bupivacaine priming. 
During the immunization trials, three of the mice showed an anaphylactic reaction in the form of 
shivers and prostration that lasted for IS to 20 minutes immediately after bupivacaine injections. 
All the mice survived die reaction and behaved normally thereafter. If fresh bupivacaine solution 
was used, no reactions were observed. Since it was not investigated further, no conclusions 
could be derived as to whether it was an individual idiosyncrasy of these mice or was due to any 
byproduct(s) generated during short-term storage of the diluted drug that led to anaphylaxis. 
The blastogenic responses did not indicate a readily identifiable effect by Es in the genetic 
vaccinates although some interesting results were observed. In contrast to the protein vaccinates, 
blastogenesis was optimal in the genetic vaccinates when the splenocytes were stimulated with 
10 |jg of antigen per ml. The P71 vaccinate group had higher stimulation indices with both the 
pVR1012 and pVR1020 plasmid backbones compared to the EsPTl vaccinates. One 
explanation mentioned above is that the sensitized lymphocytes had migrated from the spleen in 
the Es immunized mice by the time of necropsy. If lymphocyte migration had occurred, the 
blastogenic responses in lymphocytes from draining lymph nodes or blood might be revealing. 
It is generally thought that intramuscular genetic vaccination elicits an immune response in the 
spleen while intradermal vaccination elicits an immune response in the draining lymph node 
(81). If Es is accelerating splenic lymphocyte maturation and migration, intramuscular injections 
with Es might enhance the immune response in other lymphoid organs. Finally, the P71 
vaccinate groups with both vector backbones had higher stimulation indices on day 42 
compared to day 32, in contrast to the observation with the genetic P97 vaccinates. This may be 
attributed to immunogenic differences between the P97 and P71 proteins. 
A strong indicator of Type I responses is enhanced IFN-y secretion upon antigen-specific 
stimulation. The amount of IFN-y released following antigenic stimulation of sensitized 
splenocytes differed significantly between the P97 genetic vaccinates and the P97 protein 
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vaccinates. In the P97 genetic smdy, the P97 vaccinate group released very high levels of IFN-y 
on day 42 compared to the EsP97 vaccinate group. It was also noted that the IFN-y levels 
increased from day 32 to day 42 in the P97 vaccinate group while it decreased in the EsP97 
vaccinate group between the two time points, perhaps indicating again the migration of 
sensitized cells from the spleen in the Es-immunized animals. 
The plasmid backbones showed significant differences in the F71 studies. Genetic 
vaccinates with the pVR1020 backbone showed differences between P71 and EsP71 vaccinates 
while the pVR1012 backbone groups showed little difference between groups at both time 
points. The EsP71 vaccinates with the pVR1020 backbone released significantly higher levels 
of IFN-y compared to P71 vaccinates at both time points. This was not true for the pVR1012 
plasmid backbone groups. 
Another indicator of Thl responses is a decrease in IL-10 levels in stimulated sensitized 
lymphocytes. In these studies, genetic constructs with Es fusions generally had suppressed IL-
10 levels. For instance, while the splenocytes from non-Es groups with either plasmid backbone 
released IL-IO at both time points, the Es fusions showed detectable levels of IL-10 release only 
on day 42. A comparison of the IL-10 levels released by the Es fusion vaccinates with the non-
Es vaccinates showed a 4- to 5-fold reduction in IL-10 levels suggesting suppression of Type II 
responses by Es. Interestingly, the P97 genetic vaccinate group like the protein vaccinate group 
released 3 to 4 times higher levels of IL-10 compared to the P71 genetic vaccinate group. This 
may suggest that P97 is a more potent activator of IL-10 than P71. 
Genetic vaccination in mice generally produces a Type I immune response leading to high 
levels of IgG2a antibodies (79). The P97 genetic vaccinates with the pVR1012 backbone had 
significantly higher levels of IgG2a than IgGl. In fact, the IgG2a antibody levels were much 
higher compared to the IgGl levels for both P97 and P71 genetic vaccinate groups. IgGl could 
not be detected at the first time point for both P97 and EsP97 vaccinate groups. The mean 
IgG2a levels were approximately the same on day 32 for both groups as well. The mean IgG2a 
levels were decreasing in P97 vaccinates from day 32 to day 42, but the Es97 vaccinates had 
rising IgG2a levels between days 32 and 42. 
For P71 vaccinates, there were differences in the IgGl and IgG2a levels between the 
different plasmid vectors. The pVR1012 vaccinates had low levels of both IgGl and IgG2a 
compared to the pVR1020 vaccinates. Also, there appeared to be higher levels of both 
antibodies in the EsP7l pVR1012 vaccinates, but it was not significant. In the pVR1020 
vaccinates, however, there were significantly higher levels of IgG2a in the serum of EsP71 
vaccinates compared to the P71 vaccinates. The levels of IgGl in this group were also higher 
with the EsP71 vaccinate group at both time points compared to the P71 vaccinates, bi 
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summary, the pVR1020 backbone vaccinates gave conclusive evidence of an enhanced Type I 
response by all parameters measured, IFN-yand IgG2a antibody increases, and IL-10 
decreases. The pVR1012 backbone was not as robust in generating a strong antigen-specific 
Type I immune response. Future studies should employ pVR1020 or similar plasmid for 
genetic vaccine studies for maximum results. 
Based upon the results of this study, a model for enhancement of Type I inunune responses 
by ESAT-6 can be proposed (Fig. 26). The initial burst of antigen-specific INF-y release after 
priming by Es-antigen fusions, results in dedifferentiation of Th2 cells to ThO cells. Since ThO 
cells have the potential to differentiate either to Thl or Th2 cells, the preponderance of INF-y 
will result in higher numbers of Thl cells and a decline in the numbers of Th2 cells in the 
overall cell population. 
Figure 26. Proposed model for enhancement of Type I immune responses by ESAT-6. 
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CONCLUSIONS 
The winning strategy for a host against any pathogen is to elicit the proper type of 
immunity to prevent disease. A broad generalization would suggest that a humoral response 
against extracellular bacterial pathogens, a cellular response against intracellular bacterial 
pathogens, and a cytotoxic response against viruses or cancerous cells would be the most 
effective. Yet, an orchestrated effort by the various branches of immunity is required to achieve 
that end. Generating the proper immune responses in the host by vaccination is a powerful 
strategy that has evolved over the last century. The use of adjuvants in the vaccine preparations 
helps to bring about the required immunomodulation. In spite of newer vaccination techniques 
such as recombinant proteins and genetic vaccinations, there remains the need for more 
effective, specific and safe adjuvants. This study was specifically focused to that area. 
The M. tuberculosis Es protein has been shown to generate a Thl response that is involved 
in the recall of long-lived immunity and protection against tuberculosis in mice. The present 
study extended that observation by testing whether an antigen fused to Es could lead to an 
enhanced antigen-specific Type I response. In other words, could Es act as an antigen-specific 
Type I adjuvant. The test system involved Es fusions with either M. hyopneumoniae P97 and 
P71 surface antigens as recombinant protein or genetic vaccines in mice. 
The results of the study led to the conclusion that fusing antigens to Es could lead to 
enhanced antigen-specific Type I responses in mice. This is true if mice are immunized either 
with recombinant proteins or with genetic vaccines. These Type I responses were identified by 
significantly higher levels of IFN-y, suppression of IL-10 and higher levels of IgG2a antigen-
specific antibodies generated by the Es vaccinates compared to the non-Es vaccinates. This 
represents the successful culmination of a battery of experiments that tested a hitherto 
unexplored approach to enhance antigen-specific Type I responses. The results of these 
experiments help to conclude that M. tuberculosis Es protein can act as a molecular Type I 
adjuvant bodi for recombinant protein as well as genetic vaccines. It will be interesting to 
elucidate the mechanism by which Es brings about this effect. These results show that Es can 
act as both a protein and DNA vaccine adjuvant with the P97 or F71 proteins. In addition to the 
peptide sequences that are recognized for enhanced Thl responses (15), the gene sequences 
contain two lymphocyte stimulating oligonucleotide sequences orCpG motifs. They were 
located between nucleotides 175 to 180 and 265 to 270. CpG motifs have already been shown 
to enhance immune responses (59). This suggests that Es can enhance the effect of genetic 
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vaccines when included in the cloned sequence dirough two different mechanisms, one protein-
mediated and the second, nucleic acid-mediated. 
Further refining of the protocols will substantially help to take it from the bench to market. 
Once the best conditions are established, Es will find uses in several areas such as molecular 
vaccinology, cancer therapy and gene therapy as a Type I molecular adjuvant. 
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